https://www.wikidoc.org/api.php?action=feedcontributions&feedformat=atom&user=Adnan+Eziciwikidoc - User contributions [en]2026-04-18T14:58:43ZUser contributionsMediaWiki 1.45.1https://www.wikidoc.org/index.php?title=B-cell_lymphoma_laboratory_tests&diff=1726968B-cell lymphoma laboratory tests2022-06-30T14:05:49Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
<br />
==Overview==<br />
<br />
==Laboratory Findings==<br />
<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_laboratory_tests&diff=1726952B-cell lymphoma laboratory tests2022-06-30T12:35:45Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
<br />
==Overview==<br />
<br />
==Laboratory Findings==<br />
<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_physical_examination&diff=1726930B-cell lymphoma physical examination2022-06-29T14:29:36Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
<br />
==Overview==<br />
Common physical examination findings of B cell lymphomas include [[Lymphadenopathy|peripheral lymphadenopathy]], [[Lymphadenopathy|central lymphadenopathy]], [[fever]], [[pruritus]], [[pallor]], [[petechiae]], [[jaundice]], chest tenderness, [[abdominal distension]], [[abdominal tenderness]], and [[hepatosplenomegaly]].<br />
<br />
==Physical Examination==<br />
The following physical examination findings may be present among patients with B cell lymphomas:<ref name="pmid32644754">{{cite journal| author=| title=StatPearls | journal= | year= 2022 | volume= | issue= | pages= | pmid=32644754 | doi= | pmc= | url= }} </ref><ref name="pmid29763144">{{cite journal| author=| title=StatPearls | journal= | year= 2022 | volume= | issue= | pages= | pmid=29763144 | doi= | pmc= | url= }} </ref><ref name="pmid19999217">{{cite journal| author=Hingorjo MR, Syed S| title=Presentation, staging and diagnosis of lymphoma: a clinical perspective. | journal=J Ayub Med Coll Abbottabad | year= 2008 | volume= 20 | issue= 4 | pages= 100-3 | pmid=19999217 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19999217 }} </ref><ref name="pmid28153383">{{cite journal| author=Armitage JO, Gascoyne RD, Lunning MA, Cavalli F| title=Non-Hodgkin lymphoma. | journal=Lancet | year= 2017 | volume= 390 | issue= 10091 | pages= 298-310 | pmid=28153383 | doi=10.1016/S0140-6736(16)32407-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28153383 }} </ref><ref name="pmid32703953">{{cite journal| author=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH | display-authors=etal| title=Hodgkin lymphoma. | journal=Nat Rev Dis Primers | year= 2020 | volume= 6 | issue= 1 | pages= 61 | pmid=32703953 | doi=10.1038/s41572-020-0189-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32703953 }} </ref><br />
<br />
===Appearance of the Patient===<br />
*Appearance of the Patients with B cell lymphomas depends on the stage of disease. Patients may present with [[cachexic|cachexia]] in late disease stage.<br />
<br />
===Vital Signs===<br />
*Fever<br />
*[[Tachypnea]]<br />
*Asymmetric pulse<br />
<br />
===Skin===<br />
*Skin examination of patients with B cell lymphomas include:<br />
**[[Pallor]]<br />
**[[Pruritus]]<br />
**[[Petechiae]] <br />
**[[Jaundice]]<br />
<br />
===HEENT===<br />
* Abnormalities of the head/hair may include:<br />
**Icteric sclera <br />
**[[Nystagmus]] <br />
*Patients may develop superior vena cava syndrome, which may present with:<br />
**Swelling of the face<br />
**Facial flushing/redness face or cheeks<br />
**Facial tenderness<br />
**Drooping eyelid<br />
**Swelling around the eye<br />
<br />
===Neck===<br />
*[[Lymphadenopathy|Cervical lymphadenopathy]]<br />
<br />
===Lungs===<br />
*Thoracic masses suggestive of [[Lymphadenopathy|central lymphadenopathy]]<br />
*Chest tenderness<br />
*Pleural effusion may develop, which has signs and symptoms such as:<br />
**[[Wheezing]]<br />
**Decreased breath sounds<br />
**Asymmetric chest expansion<br />
**Hyperresonance lungs on chest auscultation<br />
<br />
===Heart===<br />
*Cardiovascular examination of patients with B cell lymphomas is usually normal.<br />
<br />
===Abdomen===<br />
*Abdominal examination of patients with B cell lymphomas include:<br />
**[[Abdominal distension]] <br />
**[[Abdominal tenderness]] <br />
**[[Hepatosplenomegaly]]<br />
**[[Abdominal mass]]es suggestive of [[Lymphadenopathy|central lymphadenopathy]]<br />
<br />
===Back===<br />
*Back examination of patients with B cell lymphomas is usually normal.<br />
<br />
===Genitourinary===<br />
*Genitourinary examination of patients with B cell lymphomas is usually normal.<br />
<br />
===Neuromuscular===<br />
*Neuromuscular examination of patients with B cell lymphomas is usually normal.<br />
<br />
===Extremities===<br />
*[[Lymphadenopathy|Peripheral lymphadenopathy]]<br />
*Joint pain<br />
*[[Edema]]<br />
*[[Bone fractures]]<br />
<br />
===CNS===<br />
*[[Seizures]]<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_physical_examination&diff=1726929B-cell lymphoma physical examination2022-06-29T14:28:06Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
<br />
==Overview==<br />
Common physical examination findings of B cell lymphomas include [[Lymphadenopathy|peripheral lymphadenopathy]], [[Lymphadenopathy|central lymphadenopathy]], [[fever]], [[pruritus]], [[pallor]], [[petechiae]], [[jaundice]], chest tenderness, [[abdominal distension]], [[abdominal tenderness]], [[hepatosplenomegaly]].<br />
<br />
==Physical Examination==<br />
The following physical examination findings may be present among patients with B cell lymphomas:<ref name="pmid32644754">{{cite journal| author=| title=StatPearls | journal= | year= 2022 | volume= | issue= | pages= | pmid=32644754 | doi= | pmc= | url= }} </ref><ref name="pmid29763144">{{cite journal| author=| title=StatPearls | journal= | year= 2022 | volume= | issue= | pages= | pmid=29763144 | doi= | pmc= | url= }} </ref><ref name="pmid19999217">{{cite journal| author=Hingorjo MR, Syed S| title=Presentation, staging and diagnosis of lymphoma: a clinical perspective. | journal=J Ayub Med Coll Abbottabad | year= 2008 | volume= 20 | issue= 4 | pages= 100-3 | pmid=19999217 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19999217 }} </ref><ref name="pmid28153383">{{cite journal| author=Armitage JO, Gascoyne RD, Lunning MA, Cavalli F| title=Non-Hodgkin lymphoma. | journal=Lancet | year= 2017 | volume= 390 | issue= 10091 | pages= 298-310 | pmid=28153383 | doi=10.1016/S0140-6736(16)32407-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28153383 }} </ref><ref name="pmid32703953">{{cite journal| author=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH | display-authors=etal| title=Hodgkin lymphoma. | journal=Nat Rev Dis Primers | year= 2020 | volume= 6 | issue= 1 | pages= 61 | pmid=32703953 | doi=10.1038/s41572-020-0189-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32703953 }} </ref><br />
<br />
===Appearance of the Patient===<br />
*Appearance of the Patients with B cell lymphomas depends on the stage of disease. Patients may present with [[cachexic|cachexia]] in late disease stage.<br />
<br />
===Vital Signs===<br />
*Fever<br />
*[[Tachypnea]]<br />
*Asymmetric pulse<br />
<br />
===Skin===<br />
*Skin examination of patients with B cell lymphomas include:<br />
**[[Pallor]]<br />
**[[Pruritus]]<br />
**[[Petechiae]] <br />
**[[Jaundice]]<br />
<br />
===HEENT===<br />
* Abnormalities of the head/hair may include:<br />
**Icteric sclera <br />
**[[Nystagmus]] <br />
*Patients may develop superior vena cava syndrome, which may present with:<br />
**Swelling of the face<br />
**Facial flushing/redness face or cheeks<br />
**Facial tenderness<br />
**Drooping eyelid<br />
**Swelling around the eye<br />
<br />
===Neck===<br />
*[[Lymphadenopathy|Cervical lymphadenopathy]]<br />
<br />
===Lungs===<br />
*Thoracic masses suggestive of [[Lymphadenopathy|central lymphadenopathy]]<br />
*Chest tenderness<br />
*Pleural effusion may develop, which has signs and symptoms such as:<br />
**[[Wheezing]]<br />
**Decreased breath sounds<br />
**Asymmetric chest expansion<br />
**Hyperresonance lungs on chest auscultation<br />
<br />
===Heart===<br />
*Cardiovascular examination of patients with B cell lymphomas is usually normal.<br />
<br />
===Abdomen===<br />
*Abdominal examination of patients with B cell lymphomas include:<br />
**[[Abdominal distension]] <br />
**[[Abdominal tenderness]] <br />
**[[Hepatosplenomegaly]]<br />
**[[Abdominal mass]]es suggestive of [[Lymphadenopathy|central lymphadenopathy]]<br />
<br />
===Back===<br />
*Back examination of patients with B cell lymphomas is usually normal.<br />
<br />
===Genitourinary===<br />
*Genitourinary examination of patients with B cell lymphomas is usually normal.<br />
<br />
===Neuromuscular===<br />
*Neuromuscular examination of patients with B cell lymphomas is usually normal.<br />
<br />
===Extremities===<br />
*[[Lymphadenopathy|Peripheral lymphadenopathy]]<br />
*Joint pain<br />
*[[Edema]]<br />
*[[Bone fractures]]<br />
<br />
===CNS===<br />
*[[Seizures]]<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_physical_examination&diff=1726928B-cell lymphoma physical examination2022-06-29T14:21:32Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
<br />
==Overview==<br />
The following physical examination findings may be present among patients with Hodgkin's lymphoma: [[fever]], [[pruritus]], [[petechiae]], [[jaundice]], [[Lymphadenopathy|peripheral lymphadenopathy]], [[Lymphadenopathy|central lymphadenopathy]], [[wheezing]] , chest tenderness, [[abdominal tenderness]], [[hepatomegaly]], [[splenomegaly]] and [[Lymphadenopathy|peripheral lymphadenopathy]].<br />
<br />
==Physical Examination==<br />
The following physical examination findings may be present among patients with B cell lymphomas:<ref name="pmid32644754">{{cite journal| author=| title=StatPearls | journal= | year= 2022 | volume= | issue= | pages= | pmid=32644754 | doi= | pmc= | url= }} </ref><ref name="pmid29763144">{{cite journal| author=| title=StatPearls | journal= | year= 2022 | volume= | issue= | pages= | pmid=29763144 | doi= | pmc= | url= }} </ref><ref name="pmid19999217">{{cite journal| author=Hingorjo MR, Syed S| title=Presentation, staging and diagnosis of lymphoma: a clinical perspective. | journal=J Ayub Med Coll Abbottabad | year= 2008 | volume= 20 | issue= 4 | pages= 100-3 | pmid=19999217 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19999217 }} </ref><ref name="pmid28153383">{{cite journal| author=Armitage JO, Gascoyne RD, Lunning MA, Cavalli F| title=Non-Hodgkin lymphoma. | journal=Lancet | year= 2017 | volume= 390 | issue= 10091 | pages= 298-310 | pmid=28153383 | doi=10.1016/S0140-6736(16)32407-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28153383 }} </ref><ref name="pmid32703953">{{cite journal| author=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH | display-authors=etal| title=Hodgkin lymphoma. | journal=Nat Rev Dis Primers | year= 2020 | volume= 6 | issue= 1 | pages= 61 | pmid=32703953 | doi=10.1038/s41572-020-0189-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32703953 }} </ref><br />
<br />
===Appearance of the Patient===<br />
*Appearance of the Patients with B cell lymphomas depends on the stage of disease. Patients may present with [[cachexic|cachexia]] in late disease stage.<br />
<br />
===Vital Signs===<br />
*Fever<br />
*[[Tachypnea]]<br />
*Asymmetric pulse<br />
<br />
===Skin===<br />
*Skin examination of patients with B cell lymphomas include:<br />
**[[Pallor]]<br />
**[[Pruritus]]<br />
**[[Petechiae]] <br />
**[[Jaundice]]<br />
<br />
===HEENT===<br />
* Abnormalities of the head/hair may include:<br />
**Icteric sclera <br />
**[[Nystagmus]] <br />
*Patients may develop superior vena cava syndrome, which may present with:<br />
**Swelling of the face<br />
**Facial flushing/redness face or cheeks<br />
**Facial tenderness<br />
**Drooping eyelid<br />
**Swelling around the eye<br />
<br />
===Neck===<br />
*[[Lymphadenopathy|Cervical lymphadenopathy]]<br />
<br />
===Lungs===<br />
*Thoracic masses suggestive of [[Lymphadenopathy|central lymphadenopathy]]<br />
*Chest tenderness<br />
*Pleural effusion may develop, which has signs and symptoms such as:<br />
**[[Wheezing]]<br />
**Decreased breath sounds<br />
**Asymmetric chest expansion<br />
**Hyperresonance lungs on chest auscultation<br />
<br />
===Heart===<br />
*Cardiovascular examination of patients with B cell lymphomas is usually normal.<br />
<br />
===Abdomen===<br />
*Abdominal examination of patients with B cell lymphomas include:<br />
**[[Abdominal distension]] <br />
**[[Abdominal tenderness]] <br />
**[[Hepatosplenomegaly]]<br />
**[[Abdominal mass]]es suggestive of [[Lymphadenopathy|central lymphadenopathy]]<br />
<br />
===Back===<br />
*Back examination of patients with B cell lymphomas is usually normal.<br />
<br />
===Genitourinary===<br />
*Genitourinary examination of patients with B cell lymphomas is usually normal.<br />
<br />
===Neuromuscular===<br />
*Neuromuscular examination of patients with B cell lymphomas is usually normal.<br />
<br />
===Extremities===<br />
*[[Lymphadenopathy|Peripheral lymphadenopathy]]<br />
*Joint pain<br />
*[[Edema]]<br />
*[[Bone fractures]]<br />
<br />
===CNS===<br />
*[[Seizures]]<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_physical_examination&diff=1726927B-cell lymphoma physical examination2022-06-29T13:51:12Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
The following physical examination findings may be present among patients with Hodgkin's lymphoma: [[fever]], [[pruritus]], [[petechiae]], [[jaundice]], [[Lymphadenopathy|peripheral lymphadenopathy]], [[Lymphadenopathy|central lymphadenopathy]], [[wheezing]] , chest tenderness, [[abdominal tenderness]], [[hepatomegaly]], [[splenomegaly]] and [[Lymphadenopathy|peripheral lymphadenopathy]].<ref name="pmid32644754">{{cite journal| author=| title=StatPearls | journal= | year= 2022 | volume= | issue= | pages= | pmid=32644754 | doi= | pmc= | url= }} </ref><ref name="pmid29763144">{{cite journal| author=| title=StatPearls | journal= | year= 2022 | volume= | issue= | pages= | pmid=29763144 | doi= | pmc= | url= }} </ref><ref name="pmid19999217">{{cite journal| author=Hingorjo MR, Syed S| title=Presentation, staging and diagnosis of lymphoma: a clinical perspective. | journal=J Ayub Med Coll Abbottabad | year= 2008 | volume= 20 | issue= 4 | pages= 100-3 | pmid=19999217 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19999217 }} </ref><ref name="pmid28153383">{{cite journal| author=Armitage JO, Gascoyne RD, Lunning MA, Cavalli F| title=Non-Hodgkin lymphoma. | journal=Lancet | year= 2017 | volume= 390 | issue= 10091 | pages= 298-310 | pmid=28153383 | doi=10.1016/S0140-6736(16)32407-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28153383 }} </ref><ref name="pmid32703953">{{cite journal| author=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH | display-authors=etal| title=Hodgkin lymphoma. | journal=Nat Rev Dis Primers | year= 2020 | volume= 6 | issue= 1 | pages= 61 | pmid=32703953 | doi=10.1038/s41572-020-0189-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32703953 }} </ref><br />
<br />
===Appearance of the Patient===<br />
*Appearance of the Patients with B cell lymphomas depends on the stage of disease. Patients usually appear [[cachexic|cachectic]].<br />
<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_history_and_symptoms&diff=1723981B-cell lymphoma history and symptoms2022-05-15T18:01:36Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
The hallmark of Hodgkin's lymphoma is painless supra-diaphragmatic [[lymphadenopathy]]. A positive history of [[B symptoms]] (unexplained profound weight loss, high fevers, and drenching night sweats) is suggestive of Hodgkin's lymphoma. The hallmark of non-Hodgkin lymphomas is peripheral lymphadenopathy. Patients usually have different presentations depending on the subtype, the location of involvement, and the grade of the tumor. Although episodes of waxing and waning lymphadenopathy might be seen in low-grade lymphoma, B symptoms are more likely to present in patients with a high-grade variant of non-Hodgkin lymphoma.<br />
==History and Symptoms==<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]].<br />
*The hallmark of Hodgkin's lymphoma is painless supra-diaphragmatic [[lymphadenopathy]]. A positive history of [[B symptoms]] (unexplained profound weight loss, high fevers, and drenching night sweats) is suggestive of Hodgkin's lymphoma.<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref><ref name="pmid26541251">{{cite journal |vauthors=Ansell SM |title=Hodgkin Lymphoma: Diagnosis and Treatment |journal=Mayo Clin Proc |volume=90 |issue=11 |pages=1574–83 |date=November 2015 |pmid=26541251 |doi=10.1016/j.mayocp.2015.07.005 |url=}}</ref><br />
*The hallmark of non-Hodgkin lymphomas is peripheral lymphadenopathy. Patients usually have different presentations depending on the subtype, the location of involvement, and the grade of the tumor. Although episodes of waxing and waning lymphadenopathy might be seen in low-grade lymphoma, B symptoms are more likely to present in patients with a high-grade variant of non-Hodgkin lymphoma.<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid28153383">{{cite journal |vauthors=Armitage JO, Gascoyne RD, Lunning MA, Cavalli F |title=Non-Hodgkin lymphoma |journal=Lancet |volume=390 |issue=10091 |pages=298–310 |date=July 2017 |pmid=28153383 |doi=10.1016/S0140-6736(16)32407-2 |url=}}</ref><br />
===History===<br />
*Patients with Hodgkins's lymphoma may have a positive history of:<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref><ref name="pmid26541251">{{cite journal |vauthors=Ansell SM |title=Hodgkin Lymphoma: Diagnosis and Treatment |journal=Mayo Clin Proc |volume=90 |issue=11 |pages=1574–83 |date=November 2015 |pmid=26541251 |doi=10.1016/j.mayocp.2015.07.005 |url=}}</ref><br />
**Painless supra-diaphragmatic [[lymphadenopathy]] in one to two lymph node areas generally seen in patients with Hodgkin's lymphoma.<br />
**[[B symptoms]] (unexplained profound weight loss, high fevers, and drenching night sweats) might be seen in up to 30% of patients and are usually more common in patients with advanced disease.<br />
**Alcohol-related pain in lymph nodes<br />
**Chronic [[pruritus]]<br />
**Chest pain and shortness of breath might be seen in patients with [[mediastinal]] involvement. <br />
*Patients with non-Hodgkin lymphoma may have a positive history of:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid28153383">{{cite journal |vauthors=Armitage JO, Gascoyne RD, Lunning MA, Cavalli F |title=Non-Hodgkin lymphoma |journal=Lancet |volume=390 |issue=10091 |pages=298–310 |date=July 2017 |pmid=28153383 |doi=10.1016/S0140-6736(16)32407-2 |url=}}</ref><br />
**Peripheral [[lymphadenopathy]]<br />
**Episodes of waxing and waning lymphadenopathy<br />
**[[B symptoms]], usually in patients with advanced disease<br />
===Common Symptoms===<br />
*Common symptoms of Hodgkins's lymphoma include:<ref name="urlHodgkin Lymphoma | Hodgkin Disease">{{cite web |url=https://www.cancer.org/cancer/hodgkin-lymphoma.html |title=Hodgkin Lymphoma &#124; Hodgkin Disease |format= |work= |accessdate=}}</ref><ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref<br />
**[[Lymphadenopathy]]<br />
**[[B symptoms]]:<br />
***Unexplained weight loss >10% of total body weight within the past 6 months<br />
***High fevers<br />
***Drenching night sweats<br />
**Chronic [[pruritus]]<br />
**Fatigue<br />
**Enlargement of [[mediastinal]] lymph nodes might present with:<br />
***Chest pain<br />
***Shortness of breath<br />
*Common symptoms of non-Hodgkin lymphoma include:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="urlSigns and Symptoms of Non-Hodgkin Lymphoma">{{cite web |url=https://www.cancer.org/cancer/non-hodgkin-lymphoma/detection-diagnosis-staging/signs-symptoms.html |title=Signs and Symptoms of Non-Hodgkin Lymphoma |format= |work= |accessdate=}}</ref><br />
**Peripheral [[lymphadenopathy]]<br />
**[[B symptoms]]<br />
===Less Common Symptoms===<br />
*Less common symptoms of [[non-Hodgkin lymphoma]] include:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="urlSigns and Symptoms of Non-Hodgkin Lymphoma">{{cite web |url=https://www.cancer.org/cancer/non-hodgkin-lymphoma/detection-diagnosis-staging/signs-symptoms.html |title=Signs and Symptoms of Non-Hodgkin Lymphoma |format= |work= |accessdate=}}</ref><br />
**Skin rashes<br />
**Fatigue<br />
**[[Pruritus]]<br />
**Malaise<br />
**Chest pain or pressure<br />
**[[Fever of unknown origin]]<br />
**Easy bruising or bleeding<br />
**[[Ascites]]<br />
**Effusions<br />
**Primary [[gastrointestinal tract]] lymphoma might present with:<br />
***Nausea and vomiting<br />
***Abdominal swelling<br />
***Early satiety<br />
**Primary [[central nervous system]] lymphoma might present with:<br />
***Headaches<br />
***[[Spinal cord]] compression features<br />
***Lethargy <br />
***[[Focal neurologic signs]]<br />
***[[Seizures]] <br />
***[[Paralysis]]<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_history_and_symptoms&diff=1723980B-cell lymphoma history and symptoms2022-05-15T18:00:34Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
==History and Symptoms==<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]].<br />
*The hallmark of Hodgkin's lymphoma is painless supra-diaphragmatic [[lymphadenopathy]]. A positive history of [[B symptoms]] (unexplained profound weight loss, high fevers, and drenching night sweats) is suggestive of Hodgkin's lymphoma.<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref><ref name="pmid26541251">{{cite journal |vauthors=Ansell SM |title=Hodgkin Lymphoma: Diagnosis and Treatment |journal=Mayo Clin Proc |volume=90 |issue=11 |pages=1574–83 |date=November 2015 |pmid=26541251 |doi=10.1016/j.mayocp.2015.07.005 |url=}}</ref><br />
*The hallmark of non-Hodgkin lymphomas is peripheral lymphadenopathy. Patients usually have different presentations depending on the subtype, the location of involvement, and the grade of the tumor. Although episodes of waxing and waning lymphadenopathy might be seen in low-grade lymphoma, B symptoms are more likely to present in patients with a high-grade variant of non-Hodgkin lymphoma.<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid28153383">{{cite journal |vauthors=Armitage JO, Gascoyne RD, Lunning MA, Cavalli F |title=Non-Hodgkin lymphoma |journal=Lancet |volume=390 |issue=10091 |pages=298–310 |date=July 2017 |pmid=28153383 |doi=10.1016/S0140-6736(16)32407-2 |url=}}</ref><br />
===History===<br />
*Patients with Hodgkins's lymphoma may have a positive history of:<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref><ref name="pmid26541251">{{cite journal |vauthors=Ansell SM |title=Hodgkin Lymphoma: Diagnosis and Treatment |journal=Mayo Clin Proc |volume=90 |issue=11 |pages=1574–83 |date=November 2015 |pmid=26541251 |doi=10.1016/j.mayocp.2015.07.005 |url=}}</ref><br />
**Painless supra-diaphragmatic [[lymphadenopathy]] in one to two lymph node areas generally seen in patients with Hodgkin's lymphoma.<br />
**[[B symptoms]] (unexplained profound weight loss, high fevers, and drenching night sweats) might be seen in up to 30% of patients and are usually more common in patients with advanced disease.<br />
**Alcohol-related pain in lymph nodes<br />
**Chronic [[pruritus]]<br />
**Chest pain and shortness of breath might be seen in patients with [[mediastinal]] involvement. <br />
*Patients with non-Hodgkin lymphoma may have a positive history of:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid28153383">{{cite journal |vauthors=Armitage JO, Gascoyne RD, Lunning MA, Cavalli F |title=Non-Hodgkin lymphoma |journal=Lancet |volume=390 |issue=10091 |pages=298–310 |date=July 2017 |pmid=28153383 |doi=10.1016/S0140-6736(16)32407-2 |url=}}</ref><br />
**Peripheral [[lymphadenopathy]]<br />
**Episodes of waxing and waning lymphadenopathy<br />
**[[B symptoms]], usually in patients with advanced disease<br />
===Common Symptoms===<br />
*Common symptoms of Hodgkins's lymphoma include:<ref name="urlHodgkin Lymphoma | Hodgkin Disease">{{cite web |url=https://www.cancer.org/cancer/hodgkin-lymphoma.html |title=Hodgkin Lymphoma &#124; Hodgkin Disease |format= |work= |accessdate=}}</ref><ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref<br />
**[[Lymphadenopathy]]<br />
**[[B symptoms]]:<br />
***Unexplained weight loss >10% of total body weight within the past 6 months<br />
***High fevers<br />
***Drenching night sweats<br />
**Chronic [[pruritus]]<br />
**Fatigue<br />
**Enlargement of [[mediastinal]] lymph nodes might present with:<br />
***Chest pain<br />
***Shortness of breath<br />
*Common symptoms of non-Hodgkin lymphoma include:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="urlSigns and Symptoms of Non-Hodgkin Lymphoma">{{cite web |url=https://www.cancer.org/cancer/non-hodgkin-lymphoma/detection-diagnosis-staging/signs-symptoms.html |title=Signs and Symptoms of Non-Hodgkin Lymphoma |format= |work= |accessdate=}}</ref><br />
**Peripheral [[lymphadenopathy]]<br />
**[[B symptoms]]<br />
===Less Common Symptoms===<br />
*Less common symptoms of [[non-Hodgkin lymphoma]] include:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="urlSigns and Symptoms of Non-Hodgkin Lymphoma">{{cite web |url=https://www.cancer.org/cancer/non-hodgkin-lymphoma/detection-diagnosis-staging/signs-symptoms.html |title=Signs and Symptoms of Non-Hodgkin Lymphoma |format= |work= |accessdate=}}</ref><br />
**Skin rashes<br />
**Fatigue<br />
**[[Pruritus]]<br />
**Malaise<br />
**Chest pain or pressure<br />
**[[Fever of unknown origin]]<br />
**Easy bruising or bleeding<br />
**[[Ascites]]<br />
**Effusions<br />
**Primary [[gastrointestinal tract]] lymphoma might present with:<br />
***Nausea and vomiting<br />
***Abdominal swelling<br />
***Early satiety<br />
**Primary [[central nervous system]] lymphoma might present with:<br />
***Headaches<br />
***[[Spinal cord]] compression features<br />
***Lethargy <br />
***[[Focal neurologic signs]]<br />
***[[Seizures]] <br />
***[[Paralysis]]<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_history_and_symptoms&diff=1723911B-cell lymphoma history and symptoms2022-05-14T12:15:29Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
==History and Symptoms==<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]].<br />
*The hallmark of Hodgkin's lymphoma is painless supra-diaphragmatic [[lymphadenopathy]]. A positive history of [[B symptoms]] (unexplained profound weight loss, high fevers, and drenching night sweats) is suggestive of Hodgkin's lymphoma.<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref><ref name="pmid26541251">{{cite journal |vauthors=Ansell SM |title=Hodgkin Lymphoma: Diagnosis and Treatment |journal=Mayo Clin Proc |volume=90 |issue=11 |pages=1574–83 |date=November 2015 |pmid=26541251 |doi=10.1016/j.mayocp.2015.07.005 |url=}}</ref><br />
*The hallmark of non-Hodgkin lymphomas is peripheral lymphadenopathy. Patients usually have different presentations depending on the subtype, the location of involvement, and the grade of the tumor. Although episodes of waxing and waning lymphadenopathy might be seen in low-grade lymphoma, B symptoms are more likely to present in patients with a high-grade variant of non-Hodgkin lymphoma.<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid28153383">{{cite journal |vauthors=Armitage JO, Gascoyne RD, Lunning MA, Cavalli F |title=Non-Hodgkin lymphoma |journal=Lancet |volume=390 |issue=10091 |pages=298–310 |date=July 2017 |pmid=28153383 |doi=10.1016/S0140-6736(16)32407-2 |url=}}</ref><br />
===History===<br />
*Patients with Hodgkins's lymphoma may have a positive history of:<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref><ref name="pmid26541251">{{cite journal |vauthors=Ansell SM |title=Hodgkin Lymphoma: Diagnosis and Treatment |journal=Mayo Clin Proc |volume=90 |issue=11 |pages=1574–83 |date=November 2015 |pmid=26541251 |doi=10.1016/j.mayocp.2015.07.005 |url=}}</ref><br />
**Painless supra-diaphragmatic [[lymphadenopathy]] in one to two lymph node areas generally seen in patients with Hodgkin's lymphoma.<br />
**[[B symptoms]] (unexplained profound weight loss, high fevers, and drenching night sweats) might be seen in up to 30% of patients and are usually more common in patients with advanced disease.<br />
**Alcohol-related pain in lymph nodes<br />
**Chronic [[pruritus]]<br />
**Chest pain and shortness of breath might be seen in patients with [[mediastinal]] involvement. <br />
*Patients with non-Hodgkin lymphoma may have a positive history of:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid28153383">{{cite journal |vauthors=Armitage JO, Gascoyne RD, Lunning MA, Cavalli F |title=Non-Hodgkin lymphoma |journal=Lancet |volume=390 |issue=10091 |pages=298–310 |date=July 2017 |pmid=28153383 |doi=10.1016/S0140-6736(16)32407-2 |url=}}</ref><br />
**Peripheral [[lymphadenopathy]]<br />
**Episodes of waxing and waning lymphadenopathy<br />
**[[B symptoms]], usually in patients with advanced disease<br />
===Common Symptoms===<br />
<br />
===Less Common Symptoms===<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_history_and_symptoms&diff=1723910B-cell lymphoma history and symptoms2022-05-14T12:12:39Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
==History and Symptoms==<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]].<br />
*The hallmark of Hodgkin's lymphoma is painless supra-diaphragmatic [[lymphadenopathy]]. A positive history of [[B symptoms]] (unexplained profound weight loss, high fevers, and drenching night sweats) is suggestive of Hodgkin's lymphoma.<br />
*The hallmark of non-Hodgkin lymphomas is peripheral lymphadenopathy. Patients usually have different presentations depending on the subtype, the location of involvement, and the grade of the tumor. Although episodes of waxing and waning lymphadenopathy might be seen in low-grade lymphoma, B symptoms are more likely to present in patients with a high-grade variant of non-Hodgkin lymphoma. <br />
===History===<br />
*Patients with Hodgkins's lymphoma may have a positive history of:<br />
**Painless supra-diaphragmatic [[lymphadenopathy]] in one to two lymph node areas generally seen in patients with Hodgkin's lymphoma.<br />
**[[B symptoms]] (unexplained profound weight loss, high fevers, and drenching night sweats) might be seen in up to 30% of patients and are usually more common in patients with advanced disease.<br />
**Alcohol-related pain in lymph nodes<br />
**Chronic [[pruritus]]<br />
**Chest pain and shortness of breath might be seen in patients with [[mediastinal]] involvement. <br />
*Patients with non-Hodgkin lymphoma may have a positive history of:<br />
**Peripheral [[lymphadenopathy]]<br />
**Episodes of waxing and waning lymphadenopathy<br />
**[[B symptoms]], usually in patients with advanced disease<br />
===Common Symptoms===<br />
<br />
===Less Common Symptoms===<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_diagnostic_study_of_choice&diff=1723396B-cell lymphoma diagnostic study of choice2022-05-06T16:50:11Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]]. Excisional [[lymph node biopsy]] is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.<br />
==Diagnostic Study of Choice==<br />
=== Study of choice ===<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]]. <br />
*Excisional [[lymph node biopsy]] is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref><ref name="pmid27466666">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid=27466666 |doi= |url=}}</ref><ref name="pmid28395545">{{cite journal |vauthors=Jiang M, Bennani NN, Feldman AL |title=Lymphoma classification update: B-cell non-Hodgkin lymphomas |journal=Expert Rev Hematol |volume=10 |issue=5 |pages=405–415 |date=May 2017 |pmid=28395545 |doi=10.1080/17474086.2017.1318053 |url=}}</ref><ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref><br />
*[[Fine-needle aspiration]] or core-needle biopsy specimens are usually insufficient because these methods have a low ratio of malignant cells and they do not sufficiently preserve the architecture of lymph nodes.<br />
*Diagnostic studies of B-cell lymphomas include light microscopic evaluation of pathologic sample, as well as an immunophenotypic analysis with [[immunohistochemistry]] to determine the subtype.<br />
===== Diagnostic results =====<br />
*The following findings on pathological evaluation are confirmatory for Hodgkin's lypmhoma:<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref><br />
**[[Reed-Sternberg cells]] (RS)<br />
**Lymphocyte predominant cells (LP)<br />
*The following findings on immunophenotypic analysis are confirmatory for the following types of [[non-Hodgkin's lypmhoma]]:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid27466666">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid=27466666 |doi= |url=}}</ref><br />
**MYC-IGH rearrangement detected by [[FISH]] in the presence of a [[BCL2]] negative germinal centres phenotype is definitive for diagnosis of [[Burkitt lymphoma]].<br />
**A disrupted structure of [[follicle center]] by sheets of large cells which are positive for pan-B-cell antigens (e.g., [[CD20]], CD79a) is definitive for diagnosis of [[diffuse large B-cell lymphoma]] (DLBCL).<ref name="pmid30859597">{{cite journal |vauthors=Liu Y, Barta SK |title=Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment |journal=Am J Hematol |volume=94 |issue=5 |pages=604–616 |date=May 2019 |pmid=30859597 |doi=10.1002/ajh.25460 |url=}}</ref><br />
**A [[chromosomal translocation]] t(11:14) is definitive for diagnosis of [[mantle cell lymphoma]].<ref name="pmid28699667">{{cite journal |vauthors=Vose JM |title=Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management |journal=Am J Hematol |volume=92 |issue=8 |pages=806–813 |date=August 2017 |pmid=28699667 |doi=10.1002/ajh.24797 |url=}}</ref><br />
<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_diagnostic_study_of_choice&diff=1723395B-cell lymphoma diagnostic study of choice2022-05-06T16:48:49Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
<br />
==Diagnostic Study of Choice==<br />
=== Study of choice ===<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]]. <br />
*Excisional [[lymph node biopsy]] is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref><ref name="pmid27466666">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid=27466666 |doi= |url=}}</ref><ref name="pmid28395545">{{cite journal |vauthors=Jiang M, Bennani NN, Feldman AL |title=Lymphoma classification update: B-cell non-Hodgkin lymphomas |journal=Expert Rev Hematol |volume=10 |issue=5 |pages=405–415 |date=May 2017 |pmid=28395545 |doi=10.1080/17474086.2017.1318053 |url=}}</ref><ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref><br />
*[[Fine-needle aspiration]] or core-needle biopsy specimens are usually insufficient because these methods have a low ratio of malignant cells and they do not sufficiently preserve the architecture of lymph nodes.<br />
*Diagnostic studies of B-cell lymphomas include light microscopic evaluation of pathologic sample, as well as an immunophenotypic analysis with [[immunohistochemistry]] to determine the subtype.<br />
===== Diagnostic results =====<br />
*The following findings on pathological evaluation are confirmatory for Hodgkin's lypmhoma:<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref><br />
**[[Reed-Sternberg cells]] (RS)<br />
**Lymphocyte predominant cells (LP)<br />
*The following findings on immunophenotypic analysis are confirmatory for the following types of [[non-Hodgkin's lypmhoma]]:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid27466666">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid=27466666 |doi= |url=}}</ref><br />
**MYC-IGH rearrangement detected by [[FISH]] in the presence of a [[BCL2]] negative germinal centres phenotype is definitive for diagnosis of [[Burkitt lymphoma]].<br />
**A disrupted structure of [[follicle center]] by sheets of large cells which are positive for pan-B-cell antigens (e.g., [[CD20]], CD79a) is definitive for diagnosis of [[diffuse large B-cell lymphoma]] (DLBCL).<ref name="pmid30859597">{{cite journal |vauthors=Liu Y, Barta SK |title=Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment |journal=Am J Hematol |volume=94 |issue=5 |pages=604–616 |date=May 2019 |pmid=30859597 |doi=10.1002/ajh.25460 |url=}}</ref><br />
**A [[chromosomal translocation]] t(11:14) is definitive for diagnosis of [[mantle cell lymphoma]].<ref name="pmid28699667">{{cite journal |vauthors=Vose JM |title=Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management |journal=Am J Hematol |volume=92 |issue=8 |pages=806–813 |date=August 2017 |pmid=28699667 |doi=10.1002/ajh.24797 |url=}}</ref><br />
<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_diagnostic_study_of_choice&diff=1723394B-cell lymphoma diagnostic study of choice2022-05-06T16:45:59Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
<br />
==Diagnostic Study of Choice==<br />
=== Study of choice ===<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]]. <br />
*Excisional [[lymph node biopsy]] is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref><ref name="pmid27466666">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid=27466666 |doi= |url=}}</ref><ref name="pmid28395545">{{cite journal |vauthors=Jiang M, Bennani NN, Feldman AL |title=Lymphoma classification update: B-cell non-Hodgkin lymphomas |journal=Expert Rev Hematol |volume=10 |issue=5 |pages=405–415 |date=May 2017 |pmid=28395545 |doi=10.1080/17474086.2017.1318053 |url=}}</ref><ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref><br />
*[[Fine-needle aspiration]] or core-needle biopsy specimens are usually insufficient because these methods have a low ratio of malignant cells and they do not sufficiently preserve the architecture of lymph nodes.<br />
*Diagnostic studies of B-cell lymphomas include light microscopic evaluation of pathologic sample, as well as an immunophenotypic analysis with [[immunohistochemistry]] to determine the subtype.<br />
===== Diagnostic results =====<br />
*The following findings on pathological evaluation are confirmatory for Hodgkin's lypmhoma:<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref><br />
**[[Reed-Sternberg cells]] (RS)<br />
**Lymphocyte predominant cells (LP)<br />
*The following findings on immunophenotypic analysis are confirmatory for the following types of [[non-Hodgkin's lypmhoma]]:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid27466666">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid=27466666 |doi= |url=}}</ref><br />
**MYC-IGH rearrangement detected by [[FISH]] in the presence of a [[BCL2]] negative germinal centres phenotype is definitive for the diagnosis of [[Burkitt lymphoma]].<br />
**A disrupted structure of [[follicle center]] by sheets of large cells which are positive for pan-B-cell antigens (e.g., [[CD20]], CD79a) is definitive for the diagnosis of [[diffuse large B-cell lymphoma]] (DLBCL).<ref name="pmid30859597">{{cite journal |vauthors=Liu Y, Barta SK |title=Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment |journal=Am J Hematol |volume=94 |issue=5 |pages=604–616 |date=May 2019 |pmid=30859597 |doi=10.1002/ajh.25460 |url=}}</ref><br />
**A [[chromosomal translocation]] t(11:14) is definitive for the diagnosis of [[mantle cell lymphoma]].<ref name="pmid28699667">{{cite journal |vauthors=Vose JM |title=Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management |journal=Am J Hematol |volume=92 |issue=8 |pages=806–813 |date=August 2017 |pmid=28699667 |doi=10.1002/ajh.24797 |url=}}</ref><br />
<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_diagnostic_study_of_choice&diff=1723393B-cell lymphoma diagnostic study of choice2022-05-06T16:42:37Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
<br />
==Diagnostic Study of Choice==<br />
=== Study of choice ===<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]]. <br />
*Excisional lymph node biopsy is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref><ref name="pmid27466666">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid=27466666 |doi= |url=}}</ref><ref name="pmid28395545">{{cite journal |vauthors=Jiang M, Bennani NN, Feldman AL |title=Lymphoma classification update: B-cell non-Hodgkin lymphomas |journal=Expert Rev Hematol |volume=10 |issue=5 |pages=405–415 |date=May 2017 |pmid=28395545 |doi=10.1080/17474086.2017.1318053 |url=}}</ref><ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref><br />
*Fine-needle aspiration or core-needle biopsy specimens are usually insufficien because they have a low ratio of malignant cells and they do not sufficiently preserve the architecture of lymph nodes.<br />
*Diagnostic studies of B-cell lymphomas include light microscopic evaluation of pathologic sample, as well as an immunophenotypic analysis with immunohistochemistry to determine the subtype.<br />
===== Diagnostic results =====<br />
*The following findings on pathological evaluation are confirmatory for Hodgkin's lypmhoma:<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref><br />
**Reed-Sternberg cells (RS)<br />
**Lymphocyte predominant cells (LP)<br />
*The following findings on immunophenotypic analysis are confirmatory for the following types of non-Hodgkin's lypmhoma:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid27466666">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid=27466666 |doi= |url=}}</ref><br />
**MYC-IGH rearrangement detected by [[FISH]] in the presence of a [[BCL2]] negative germinal centres phenotype is definitive for the diagnosis of [[Burkitt lymphoma]].<br />
**A disrupted structure of [[follicle center]] by sheets of large cells which are positive for pan-B-cell antigens (e.g., [[CD20]], CD79a) is definitive for the diagnosis of [[diffuse large B-cell lymphoma]] (DLBCL).<ref name="pmid30859597">{{cite journal |vauthors=Liu Y, Barta SK |title=Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment |journal=Am J Hematol |volume=94 |issue=5 |pages=604–616 |date=May 2019 |pmid=30859597 |doi=10.1002/ajh.25460 |url=}}</ref><br />
**A [[chromosomal translocation]] t(11:14) is definitive for the diagnosis of [[mantle cell lymphoma]].<ref name="pmid28699667">{{cite journal |vauthors=Vose JM |title=Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management |journal=Am J Hematol |volume=92 |issue=8 |pages=806–813 |date=August 2017 |pmid=28699667 |doi=10.1002/ajh.24797 |url=}}</ref><br />
<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_diagnostic_study_of_choice&diff=1723392B-cell lymphoma diagnostic study of choice2022-05-06T16:42:12Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
<br />
==Diagnostic Study of Choice==<br />
=== Study of choice ===<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]]. <br />
*Excisional lymph node biopsy is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref><ref name="pmid27466666">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid=27466666 |doi= |url=}}</ref><ref name="pmid28395545">{{cite journal |vauthors=Jiang M, Bennani NN, Feldman AL |title=Lymphoma classification update: B-cell non-Hodgkin lymphomas |journal=Expert Rev Hematol |volume=10 |issue=5 |pages=405–415 |date=May 2017 |pmid=28395545 |doi=10.1080/17474086.2017.1318053 |url=}}</ref><ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref><br />
*Fine-needle aspiration or core-needle biopsy specimens are usually insufficien because they have a low ratio of malignant cells and they do not sufficiently preserve the architecture of lymph nodes.<br />
*Diagnostic studies of B-cell lymphomas include light microscopic evaluation of pathologic sample, as well as an immunophenotypic analysis with immunohistochemistry to determine the subtype.<br />
===== Diagnostic results =====<br />
*The following findings on performing pathological evaluation are confirmatory for Hodgkin's lypmhoma:<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref><br />
**Reed-Sternberg cells (RS)<br />
**Lymphocyte predominant cells (LP)<br />
*The following findings on immunophenotypic analysis are confirmatory for the following types of non-Hodgkin's lypmhoma:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid27466666">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid=27466666 |doi= |url=}}</ref><br />
**MYC-IGH rearrangement detected by [[FISH]] in the presence of a [[BCL2]] negative germinal centres phenotype is definitive for the diagnosis of [[Burkitt lymphoma]].<br />
**A disrupted structure of [[follicle center]] by sheets of large cells which are positive for pan-B-cell antigens (e.g., [[CD20]], CD79a) is definitive for the diagnosis of [[diffuse large B-cell lymphoma]] (DLBCL).<ref name="pmid30859597">{{cite journal |vauthors=Liu Y, Barta SK |title=Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment |journal=Am J Hematol |volume=94 |issue=5 |pages=604–616 |date=May 2019 |pmid=30859597 |doi=10.1002/ajh.25460 |url=}}</ref><br />
**A [[chromosomal translocation]] t(11:14) is definitive for the diagnosis of [[mantle cell lymphoma]].<ref name="pmid28699667">{{cite journal |vauthors=Vose JM |title=Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management |journal=Am J Hematol |volume=92 |issue=8 |pages=806–813 |date=August 2017 |pmid=28699667 |doi=10.1002/ajh.24797 |url=}}</ref><br />
<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_diagnostic_study_of_choice&diff=1723390B-cell lymphoma diagnostic study of choice2022-05-06T10:37:36Z<p>Adnan Ezici: Created page with "__NOTOC__ {{B-cell lymphoma}} {{CMG}} ; {{AE}} {{Adnan Ezici}} ==Overview== ==Diagnostic Study of Choice== === Study of choice === B-cell lymphomas include both Hodgkin's lymphomas and most Non-Hodgkin lymphomas. *Excisional lymph node biopsy is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.<ref name=..."</p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
<br />
==Diagnostic Study of Choice==<br />
=== Study of choice ===<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]]. <br />
*Excisional lymph node biopsy is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref><ref name="pmid27466666">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid=27466666 |doi= |url=}}</ref><ref name="pmid28395545">{{cite journal |vauthors=Jiang M, Bennani NN, Feldman AL |title=Lymphoma classification update: B-cell non-Hodgkin lymphomas |journal=Expert Rev Hematol |volume=10 |issue=5 |pages=405–415 |date=May 2017 |pmid=28395545 |doi=10.1080/17474086.2017.1318053 |url=}}</ref><ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref><br />
*Fine-needle aspiration or core-needle biopsy specimens are usually insufficien because they have a low ratio of malignant cells and they do not sufficiently preserve the architecture of lymph nodes.<br />
*Diagnostic studies of B-cell lymphomas include light microscopic evaluation of pathologic sample, as well as an immunophenotypic analysis with immunohistochemistry to determine the subtype.<br />
===== Diagnostic results =====<br />
*The following findings on performing pathological evaluation are confirmatory for Hodgkin's lypmhoma:<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref><br />
**Reed-Sternberg cells (RS)<br />
**Lymphocyte predominant cells (LP)<br />
*The following findings on immunophenotypic analysis are confirmatory for the following types of non-Hodgkin's lypmhoma:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><br />
**<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_natural_history,_complications_and_prognosis&diff=1723161B-cell lymphoma natural history, complications and prognosis2022-04-30T23:13:39Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]]. 30% of patients with [[Hodgkin's lymphoma]] may progress to develop [[B symptoms]]. The natural history of [[Non-Hodgkin lymphomas]] significantly varies depending on the subtype and its prognosis. Complications of B cell lymphomas are usually due to side effects of [[chemotherapy]] and/or [[radiotherapy]]. Depending on the stage of the [[Hodgkin's lymphoma]] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as excellent. The prognosis of [[non-Hodgkin's lymphoma]] (NHL) varies with the [[histopathology]], the extent of involvement, and patient factors. Low-grade lymphomas have the most favorable prognosis.<br />
==Natural History, Complications, and Prognosis==<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]].<br />
===Natural History===<br />
*30% of patients with [[Hodgkin's lymphoma]] may progress to develop [[B symptoms]] (unintentional weight loss, fever, drenching night sweats)<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref>. <br />
*The natural history of [[Non-Hodgkin lymphomas]] significantly varies depending on the subtype and its prognosis. If left untreated, aggresive lymphomas present with B symptoms, and patients' condition significantly deteriorates within days or weeks. On the other hand, indolent lymphomas usually present with waxing and waning [[lymphadenopathy]] for years<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref>.<br />
===Complications===<br />
*Complications of B cell lymphomas are usually due to side effects of [[chemotherapy]] and/or [[radiotherapy]]. <br />
**Complications in patients with [[Hodgkin's lymphoma]] include:<br />
***Common complications of chemotherapy and/or radiotherapy in patients with [[Hodgkin's lymphoma]] include:<ref name="Cancer.ca">Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015</ref><ref name="urlRadiation Therapy for Hodgkin Lymphoma | Radiation for Hodgkin Disease">{{cite web |url=https://www.cancer.org/cancer/hodgkin-lymphoma/treating/radiation.html |title=Radiation Therapy for Hodgkin Lymphoma &#124; Radiation for Hodgkin Disease |format= |work= |accessdate=}}</ref><br />
****Nausea and vomiting<br />
****[[Xerostomia]]<br />
****Sore throat<br />
****[[Dysgeusia]]<br />
****Diarrhea<br />
****Fatigue<br />
****Skin reactions<br />
***Late and long-term complications of chemotherapy and/or [[radiotherapy]] in patients with Hodgkin's lymphoma include:<ref name="Cancer.ca">Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015</ref><ref name="urlRadiation Therapy for Hodgkin Lymphoma | Radiation for Hodgkin Disease">{{cite web |url=https://www.cancer.org/cancer/hodgkin-lymphoma/treating/radiation.html |title=Radiation Therapy for Hodgkin Lymphoma &#124; Radiation for Hodgkin Disease |format= |work= |accessdate=}}</ref><br />
****Second malignancies (e.g., [[breast cancer]], [[lung cancer]], [[colon cancer]], [[leukemias]], [[non-Hodgkin lymphomas]], etc.)<ref name="pmid26699166">{{cite journal |vauthors=Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE |title=Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma |journal=N Engl J Med |volume=373 |issue=26 |pages=2499–511 |date=December 2015 |pmid=26699166 |doi=10.1056/NEJMoa1505949 |url=}}</ref><ref name="pmid16369761">{{cite journal |vauthors=Borchmann P, Behringer K, Josting A, Rueffer JU, Schnell R, Diehl V, Engert A, Kvasnicka HM, Thiele J |title=[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma] |language=German |journal=Pathologe |volume=27 |issue=1 |pages=47–52 |date=February 2006 |pmid=16369761 |doi=10.1007/s00292-005-0811-0 |url=}}</ref><ref name="pmid10653864">{{cite journal |vauthors=van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R, Aleman BM |title=Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood |journal=J Clin Oncol |volume=18 |issue=3 |pages=487–97 |date=February 2000 |pmid=10653864 |doi=10.1200/JCO.2000.18.3.487 |url=}}</ref><br />
****[[Infertility]]<br />
****Infections<br />
****[[Hypothyroidism]]<br />
****[[Dyspnea]]<br />
****Growth delay in children<br />
****[[Cardiovascular]] complications (e.g., [[congestive heart failure]], [[cardiomyopathies]], [[myocardial infarction]], [[pericarditis]], [[arryhtmias]], etc.)<ref name="pmid21483015">{{cite journal |vauthors=Ng AK, LaCasce A, Travis LB |title=Long-term complications of lymphoma and its treatment |journal=J Clin Oncol |volume=29 |issue=14 |pages=1885–92 |date=May 2011 |pmid=21483015 |doi=10.1200/JCO.2010.32.8427 |url=}}</ref><ref name="pmid20858859">{{cite journal |vauthors=Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, Marcus KJ, Stevenson MA, Chen MH, Ng AK |title=Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation |journal=Blood |volume=117 |issue=2 |pages=412–8 |date=January 2011 |pmid=20858859 |doi=10.1182/blood-2010-06-291328 |url=}}</ref><ref name="pmid24559287">{{cite journal |vauthors=Zinzani PL, Federico M, Oliva S, Pinto A, Rigacci L, Specchia G, Tucci A, Vitolo U |title=The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma |journal=Leuk Lymphoma |volume=56 |issue=1 |pages=12–25 |date=January 2015 |pmid=24559287 |doi=10.3109/10428194.2014.894187 |url=}}</ref><br />
**Complications in patients with [[non-Hodgkin's lymphoma]] include:<br />
***Common complications of [[chemotherapy]] and/or [[radiotherapy]] in patients with [[non-Hodgkin lymphoma]] include:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><br />
****Nausea and vomiting<br />
****Fatigue<br />
****[[Myelosuppression]]<br />
****[[Febrile neutropenia]]<br />
****[[Immunosuppression]]<br />
***Late and long-term complications of chemotherapy and/or radiotherapy in patients with non-Hodgkin lymphoma include:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid21483015">{{cite journal |vauthors=Ng AK, LaCasce A, Travis LB |title=Long-term complications of lymphoma and its treatment |journal=J Clin Oncol |volume=29 |issue=14 |pages=1885–92 |date=May 2011 |pmid=21483015 |doi=10.1200/JCO.2010.32.8427 |url=}}</ref><br />
****Second malignancies (e.g., [[myelodysplastic syndrome]], [[acute myeloid leukemia]], [[bladder cancer]], [[lung cancer]], [[gastrointestinal tract cancer]], [[breast cancer]], [[skin cancer]], [[Head and neck cancer|squamous cell carcinoma of the head and neck]])<br />
****Cardiovascular complications (e.g., [[cardiomyopathies]], [[congestive heart failure]], [[myocardial infarction]])<br />
****[[Infertility]]<br />
****[[Hypothyroidism]]<br />
****[[Growth hormone deficiency]]<br />
****[[Insulin resistance]]<br />
****[[Hypogonadism]]<br />
****[[Dyslipidemia]]<br />
****[[Post-traumatic stress disorder]]<br />
****[[Progressive multifocal leukoencephalopathy]] (in patients treated with an [[Rituximab|anti-CD20 monoclonal antibody]])<br />
<br />
===Prognosis===<br />
*Depending on the stage of the [[Hodgkin's lymphoma]] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as excellent.<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref> <br />
**In patients with stage 1 or 2a Hodgkin's lymphoma, the 5-year overall survival is approximately 90%. <br />
**In patients with stage 4 Hodgkin's lymphoma, the 5-year overall survival is approximately 60%. <br />
*The prognosis of [[non-Hodgkin's lymphoma]] (NHL) varies with the [[histopathology]], the extent of involvement, and patient factors. Low-grade lymphomas have the most favorable prognosis.<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="urlSurvival Rates and Factors That Affect Prognosis (Outlook) for Non-Hodgkin Lymphoma">{{cite web |url=https://www.cancer.org/cancer/non-hodgkin-lymphoma/detection-diagnosis-staging/factors-prognosis.html |title=Survival Rates and Factors That Affect Prognosis (Outlook) for Non-Hodgkin Lymphoma |format= |work= |accessdate=}}</ref><br />
**International Prognostic Index (IPI) is the main prognostic tool for NHL to determine the risk, which consists of five factors, including age >60 years, an increased serum [[LDH]] level, more than one extranodal involvement, Eastern Cooperative oncology group (ECOG) performance status 2 or greater than 2, and clinical stage III or IV.<br />
**Patients with aggressive [[Natural killer cell|NK]] or [[T cell lymphoma|T cell lymphomas]] generally have the worst prognosis. In addition, patients with [[immunodeficiency]] states have a poor response to treatment.<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_natural_history,_complications_and_prognosis&diff=1723160B-cell lymphoma natural history, complications and prognosis2022-04-30T23:10:01Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
==Natural History, Complications, and Prognosis==<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]].<br />
===Natural History===<br />
*30% of patients with [[Hodgkin's lymphoma]] may progress to develop [[B symptoms]] (unintentional weight loss, fever, drenching night sweats)<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref>. <br />
*Natural history of [[Non-Hodgkin lymphomas]] significantly varies depending on the subtype and it's prognosis. If left untreated, aggresive lymphomas present with B symptoms, and patients' condition significantly deteriorates within days or weeks. On the other hand, indolent lymphomas usually present with waxing and waning [[lymphadenopathy]] for years<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref>.<br />
===Complications===<br />
*Complications of B cell lymphomas are usually due to side effects of [[chemotherapy]] and/or [[radiotherapy]]. <br />
**Complications in patients with [[Hodgkin's lymphoma]] include:<br />
***Common complications of chemotherapy and/or radiotherapy in patients with [[Hodgkin's lymphoma]] include:<ref name="Cancer.ca">Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015</ref><ref name="urlRadiation Therapy for Hodgkin Lymphoma | Radiation for Hodgkin Disease">{{cite web |url=https://www.cancer.org/cancer/hodgkin-lymphoma/treating/radiation.html |title=Radiation Therapy for Hodgkin Lymphoma &#124; Radiation for Hodgkin Disease |format= |work= |accessdate=}}</ref><br />
****Nausea and vomiting<br />
****[[Xerostomia]]<br />
****Sore throat<br />
****[[Dysgeusia]]<br />
****Diarrhea<br />
****Fatigue<br />
****Skin reactions<br />
***Late and long-term complications of chemotherapy and/or [[radiotherapy]] in patients with Hodgkin's lymphoma include:<ref name="Cancer.ca">Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015</ref><ref name="urlRadiation Therapy for Hodgkin Lymphoma | Radiation for Hodgkin Disease">{{cite web |url=https://www.cancer.org/cancer/hodgkin-lymphoma/treating/radiation.html |title=Radiation Therapy for Hodgkin Lymphoma &#124; Radiation for Hodgkin Disease |format= |work= |accessdate=}}</ref><br />
****Second malignancies (e.g., [[breast cancer]], [[lung cancer]], [[colon cancer]], [[leukemias]], [[non-Hodgkin lymphomas]], etc.)<ref name="pmid26699166">{{cite journal |vauthors=Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE |title=Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma |journal=N Engl J Med |volume=373 |issue=26 |pages=2499–511 |date=December 2015 |pmid=26699166 |doi=10.1056/NEJMoa1505949 |url=}}</ref><ref name="pmid16369761">{{cite journal |vauthors=Borchmann P, Behringer K, Josting A, Rueffer JU, Schnell R, Diehl V, Engert A, Kvasnicka HM, Thiele J |title=[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma] |language=German |journal=Pathologe |volume=27 |issue=1 |pages=47–52 |date=February 2006 |pmid=16369761 |doi=10.1007/s00292-005-0811-0 |url=}}</ref><ref name="pmid10653864">{{cite journal |vauthors=van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R, Aleman BM |title=Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood |journal=J Clin Oncol |volume=18 |issue=3 |pages=487–97 |date=February 2000 |pmid=10653864 |doi=10.1200/JCO.2000.18.3.487 |url=}}</ref><br />
****[[Infertility]]<br />
****Infections<br />
****[[Hypothyroidism]]<br />
****[[Dyspnea]]<br />
****Growth delay in children<br />
****[[Cardiovascular]] complications (e.g., [[congestive heart failure]], [[cardiomyopathies]], [[myocardial infarction]], [[pericarditis]], [[arryhtmias]], etc.)<ref name="pmid21483015">{{cite journal |vauthors=Ng AK, LaCasce A, Travis LB |title=Long-term complications of lymphoma and its treatment |journal=J Clin Oncol |volume=29 |issue=14 |pages=1885–92 |date=May 2011 |pmid=21483015 |doi=10.1200/JCO.2010.32.8427 |url=}}</ref><ref name="pmid20858859">{{cite journal |vauthors=Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, Marcus KJ, Stevenson MA, Chen MH, Ng AK |title=Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation |journal=Blood |volume=117 |issue=2 |pages=412–8 |date=January 2011 |pmid=20858859 |doi=10.1182/blood-2010-06-291328 |url=}}</ref><ref name="pmid24559287">{{cite journal |vauthors=Zinzani PL, Federico M, Oliva S, Pinto A, Rigacci L, Specchia G, Tucci A, Vitolo U |title=The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma |journal=Leuk Lymphoma |volume=56 |issue=1 |pages=12–25 |date=January 2015 |pmid=24559287 |doi=10.3109/10428194.2014.894187 |url=}}</ref><br />
**Complications in patients with [[non-Hodgkin's lymphoma]] include:<br />
***Common complications of [[chemotherapy]] and/or [[radiotherapy]] in patients with [[non-Hodgkin lymphoma]] include:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><br />
****Nausea and vomiting<br />
****Fatigue<br />
****[[Myelosuppression]]<br />
****[[Febrile neutropenia]]<br />
****[[Immunosuppression]]<br />
***Late and long-term complications of chemotherapy and/or radiotherapy in patients with non-Hodgkin lymphoma include:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid21483015">{{cite journal |vauthors=Ng AK, LaCasce A, Travis LB |title=Long-term complications of lymphoma and its treatment |journal=J Clin Oncol |volume=29 |issue=14 |pages=1885–92 |date=May 2011 |pmid=21483015 |doi=10.1200/JCO.2010.32.8427 |url=}}</ref><br />
****Second malignancies (e.g., [[myelodysplastic syndrome]], [[acute myeloid leukemia]], [[bladder cancer]], [[lung cancer]], [[gastrointestinal tract cancer]], [[breast cancer]], [[skin cancer]], [[Head and neck cancer|squamous cell carcinoma of the head and neck]])<br />
****Cardiovascular complications (e.g., [[cardiomyopathies]], [[congestive heart failure]], [[myocardial infarction]])<br />
****[[Infertility]]<br />
****[[Hypothyroidism]]<br />
****[[Growth hormone deficiency]]<br />
****[[Insulin resistance]]<br />
****[[Hypogonadism]]<br />
****[[Dyslipidemia]]<br />
****[[Post-traumatic stress disorder]]<br />
****[[Progressive multifocal leukoencephalopathy]] (in patients treated with an [[Rituximab|anti-CD20 monoclonal antibody]])<br />
<br />
===Prognosis===<br />
*Depending on the stage of the [[Hodgkin's lymphoma]] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as excellent.<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref> <br />
**In patients with stage 1 or 2a Hodgkin's lymphoma, the 5-year overall survival is approximately 90%. <br />
**In patients with stage 4 Hodgkin's lymphoma, the 5-year overall survival is approximately 60%. <br />
*The prognosis of [[non-Hodgkin's lymphoma]] (NHL) varies with the [[histopathology]], extent of involvement, and patient factors. Low-grade lymphomas have the most favorable prognosis.<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="urlSurvival Rates and Factors That Affect Prognosis (Outlook) for Non-Hodgkin Lymphoma">{{cite web |url=https://www.cancer.org/cancer/non-hodgkin-lymphoma/detection-diagnosis-staging/factors-prognosis.html |title=Survival Rates and Factors That Affect Prognosis (Outlook) for Non-Hodgkin Lymphoma |format= |work= |accessdate=}}</ref><br />
**International Prognostic Index (IPI) is the main prognostic tool for NHL to determine the risk, which consists of five factors, including age >60 years, an increased serum [[LDH]] level, more than one extranodal involvement, Eastern Cooperative oncology group (ECOG) performance status 2 or greater than 2, and clinical stage III or IV.<br />
**Patients with aggressive [[Natural killer cell|NK]] or [[T cell lymphoma|T cell lymphomas]] generally have the worst prognosis. In addition, patients with [[immunodeficiency]] states have a poor response to treatment.<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_natural_history,_complications_and_prognosis&diff=1722602B-cell lymphoma natural history, complications and prognosis2022-04-19T18:59:21Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
==Natural History, Complications, and Prognosis==<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]].<br />
===Natural History===<br />
*30% of patients with [[Hodgkin's lymphoma]] may progress to develop [[B symptoms]] (unintentional weight loss, fever, drenching night sweats)<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref>. <br />
*Natural history of [[Non-Hodgkin lymphomas]] significantly varies depending on the subtype and it's prognosis. If left untreated, aggresive lymphomas present with B symptoms, and patients' condition significantly deteriorates within days or weeks. On the other hand, indolent lymphomas usually present with waxing and waning [[lymphadenopathy]] for years<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref>.<br />
===Complications===<br />
*Complications of B cell lymphomas are usually due to side effects of [[chemotherapy]] and/or [[radiotherapy]]. <br />
**Complications in patients with [[Hodgkin's lymphoma]] include:<br />
***Common complications of chemotherapy and/or radiotherapy in patients with [[Hodgkin's lymphoma]] include:<ref name="Cancer.ca">Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015</ref><ref name="urlRadiation Therapy for Hodgkin Lymphoma | Radiation for Hodgkin Disease">{{cite web |url=https://www.cancer.org/cancer/hodgkin-lymphoma/treating/radiation.html |title=Radiation Therapy for Hodgkin Lymphoma &#124; Radiation for Hodgkin Disease |format= |work= |accessdate=}}</ref><br />
****Nausea and vomiting<br />
****[[Xerostomia]]<br />
****Sore throat<br />
****[[Dysgeusia]]<br />
****Diarrhea<br />
****Fatigue<br />
****Skin reactions<br />
***Late and long-term complications of chemotherapy and/or [[radiotherapy]] in patients with Hodgkin's lymphoma include:<ref name="Cancer.ca">Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015</ref><ref name="urlRadiation Therapy for Hodgkin Lymphoma | Radiation for Hodgkin Disease">{{cite web |url=https://www.cancer.org/cancer/hodgkin-lymphoma/treating/radiation.html |title=Radiation Therapy for Hodgkin Lymphoma &#124; Radiation for Hodgkin Disease |format= |work= |accessdate=}}</ref><br />
****Second malignancies (e.g., [[breast cancer]], [[lung cancer]], [[colon cancer]], [[leukemias]], [[non-Hodgkin lymphomas]], etc.)<ref name="pmid26699166">{{cite journal |vauthors=Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE |title=Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma |journal=N Engl J Med |volume=373 |issue=26 |pages=2499–511 |date=December 2015 |pmid=26699166 |doi=10.1056/NEJMoa1505949 |url=}}</ref><ref name="pmid16369761">{{cite journal |vauthors=Borchmann P, Behringer K, Josting A, Rueffer JU, Schnell R, Diehl V, Engert A, Kvasnicka HM, Thiele J |title=[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma] |language=German |journal=Pathologe |volume=27 |issue=1 |pages=47–52 |date=February 2006 |pmid=16369761 |doi=10.1007/s00292-005-0811-0 |url=}}</ref><ref name="pmid10653864">{{cite journal |vauthors=van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R, Aleman BM |title=Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood |journal=J Clin Oncol |volume=18 |issue=3 |pages=487–97 |date=February 2000 |pmid=10653864 |doi=10.1200/JCO.2000.18.3.487 |url=}}</ref><br />
****[[Infertility]]<br />
****Infections<br />
****[[Hypothyroidism]]<br />
****[[Dyspnea]]<br />
****Growth delay in children<br />
****[[Cardiovascular]] complications (e.g., [[congestive heart failure]], [[cardiomyopathies]], [[myocardial infarction]], [[pericarditis]], [[arryhtmias]], etc.)<ref name="pmid21483015">{{cite journal |vauthors=Ng AK, LaCasce A, Travis LB |title=Long-term complications of lymphoma and its treatment |journal=J Clin Oncol |volume=29 |issue=14 |pages=1885–92 |date=May 2011 |pmid=21483015 |doi=10.1200/JCO.2010.32.8427 |url=}}</ref><ref name="pmid20858859">{{cite journal |vauthors=Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, Marcus KJ, Stevenson MA, Chen MH, Ng AK |title=Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation |journal=Blood |volume=117 |issue=2 |pages=412–8 |date=January 2011 |pmid=20858859 |doi=10.1182/blood-2010-06-291328 |url=}}</ref><ref name="pmid24559287">{{cite journal |vauthors=Zinzani PL, Federico M, Oliva S, Pinto A, Rigacci L, Specchia G, Tucci A, Vitolo U |title=The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma |journal=Leuk Lymphoma |volume=56 |issue=1 |pages=12–25 |date=January 2015 |pmid=24559287 |doi=10.3109/10428194.2014.894187 |url=}}</ref><br />
**Complications in patients with [[non-Hodgkin's lymphoma]] include:<br />
***Common complications of [[chemotherapy]] and/or [[radiotherapy]] in patients with [[non-Hodgkin lymphoma]] include:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><br />
****Nausea and vomiting<br />
****Fatigue<br />
****[[Myelosuppression]]<br />
****[[Febrile neutropenia]]<br />
****[[Immunosuppression]]<br />
***Late and long-term complications of chemotherapy and/or radiotherapy in patients with non-Hodgkin lymphoma include:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid21483015">{{cite journal |vauthors=Ng AK, LaCasce A, Travis LB |title=Long-term complications of lymphoma and its treatment |journal=J Clin Oncol |volume=29 |issue=14 |pages=1885–92 |date=May 2011 |pmid=21483015 |doi=10.1200/JCO.2010.32.8427 |url=}}</ref><br />
****Second malignancies (e.g., [[myelodysplastic syndrome]], [[acute myeloid leukemia]], [[bladder cancer]], [[lung cancer]], [[gastrointestinal tract cancer]], [[breast cancer]], [[skin cancer]], [[Head and neck cancer|squamous cell carcinoma of the head and neck]])<br />
****Cardiovascular complications (e.g., [[cardiomyopathies]], [[congestive heart failure]], [[myocardial infarction]])<br />
****[[Infertility]]<br />
****[[Hypothyroidism]]<br />
****[[Growth hormone deficiency]]<br />
****[[Insulin resistance]]<br />
****[[Hypogonadism]]<br />
****[[Dyslipidemia]]<br />
****[[Post-traumatic stress disorder]]<br />
****[[Progressive multifocal leukoencephalopathy]] (in patients treated with an [[Rituximab|anti-CD20 monoclonal antibody]])<br />
<br />
===Prognosis===<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_natural_history,_complications_and_prognosis&diff=1722601B-cell lymphoma natural history, complications and prognosis2022-04-19T18:57:09Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
==Natural History, Complications, and Prognosis==<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]].<br />
===Natural History===<br />
*30% of patients with [[Hodgkin's lymphoma]] may progress to develop [[B symptoms]] (unintentional weight loss, fever, drenching night sweats)<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref>. <br />
*Natural history of [[Non-Hodgkin lymphomas]] significantly varies depending on the subtype and it's prognosis. If left untreated, aggresive lymphomas present with B symptoms, and patients' condition significantly deteriorates within days or weeks. On the other hand, indolent lymphomas usually present with waxing and waning [[lymphadenopathy]] for years<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref>.<br />
===Complications===<br />
*Complications of B cell lymphomas are usually due to side effects of [[chemotherapy]] and/or [[radiotherapy]]. <br />
**Complications in patients with [[Hodgkin's lymphoma]] include:<br />
***Common complications of chemotherapy and/or radiotherapy in patients with [[Hodgkin's lymphoma]] include:<ref name="Cancer.ca">Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015</ref><ref name="urlRadiation Therapy for Hodgkin Lymphoma | Radiation for Hodgkin Disease">{{cite web |url=https://www.cancer.org/cancer/hodgkin-lymphoma/treating/radiation.html |title=Radiation Therapy for Hodgkin Lymphoma &#124; Radiation for Hodgkin Disease |format= |work= |accessdate=}}</ref><br />
****Nausea and vomiting<br />
****[[Xerostomia]]<br />
****Sore throat<br />
****[[Dysgeusia]]<br />
****Diarrhea<br />
****Fatigue<br />
****Skin reactions<br />
***Late and long-term complications of chemotherapy and/or [[radiotherapy]] in patients with Hodgkin's lymphoma include:<ref name="Cancer.ca">Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015</ref><ref name="urlRadiation Therapy for Hodgkin Lymphoma | Radiation for Hodgkin Disease">{{cite web |url=https://www.cancer.org/cancer/hodgkin-lymphoma/treating/radiation.html |title=Radiation Therapy for Hodgkin Lymphoma &#124; Radiation for Hodgkin Disease |format= |work= |accessdate=}}</ref><br />
****Second malignancies (e.g., [[breast cancer]], [[lung cancer]], [[colon cancer]], [[leukemias]], [[non-Hodgkin lymphomas]], etc.)<ref name="pmid26699166">{{cite journal |vauthors=Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE |title=Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma |journal=N Engl J Med |volume=373 |issue=26 |pages=2499–511 |date=December 2015 |pmid=26699166 |doi=10.1056/NEJMoa1505949 |url=}}</ref><ref name="pmid16369761">{{cite journal |vauthors=Borchmann P, Behringer K, Josting A, Rueffer JU, Schnell R, Diehl V, Engert A, Kvasnicka HM, Thiele J |title=[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma] |language=German |journal=Pathologe |volume=27 |issue=1 |pages=47–52 |date=February 2006 |pmid=16369761 |doi=10.1007/s00292-005-0811-0 |url=}}</ref><ref name="pmid10653864">{{cite journal |vauthors=van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R, Aleman BM |title=Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood |journal=J Clin Oncol |volume=18 |issue=3 |pages=487–97 |date=February 2000 |pmid=10653864 |doi=10.1200/JCO.2000.18.3.487 |url=}}</ref><br />
****[[Infertility]]<br />
****Infections<br />
****[[Hypothyroidism]]<br />
****[[Dyspnea]]<br />
****Growth delay in children<br />
****[[Cardiovascular]] complications (e.g., [[congestive heart failure]], [[cardiomyopathies]], [[myocardial infarction]], [[pericarditis]], [[arryhtmias]], etc.)<ref name="pmid21483015">{{cite journal |vauthors=Ng AK, LaCasce A, Travis LB |title=Long-term complications of lymphoma and its treatment |journal=J Clin Oncol |volume=29 |issue=14 |pages=1885–92 |date=May 2011 |pmid=21483015 |doi=10.1200/JCO.2010.32.8427 |url=}}</ref><ref name="pmid20858859">{{cite journal |vauthors=Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, Marcus KJ, Stevenson MA, Chen MH, Ng AK |title=Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation |journal=Blood |volume=117 |issue=2 |pages=412–8 |date=January 2011 |pmid=20858859 |doi=10.1182/blood-2010-06-291328 |url=}}</ref><ref name="pmid24559287">{{cite journal |vauthors=Zinzani PL, Federico M, Oliva S, Pinto A, Rigacci L, Specchia G, Tucci A, Vitolo U |title=The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma |journal=Leuk Lymphoma |volume=56 |issue=1 |pages=12–25 |date=January 2015 |pmid=24559287 |doi=10.3109/10428194.2014.894187 |url=}}</ref><br />
**Complications in patients with [[non-Hodgkin's lymphoma]] include:<br />
***Common complications of [[chemotherapy]] and/or [[radiotherapy]] in patients with [[non-Hodgkin lymphoma]] include:<br />
****Nausea and vomiting<br />
****Fatigue<br />
****[[Myelosuppression]]<br />
****[[Febrile neutropenia]]<br />
****[[Immunosuppression]]<br />
***Late and long-term complications of chemotherapy and/or radiotherapy in patients with non-Hodgkin lymphoma include:<br />
****Second malignancies (e.g., [[myelodysplastic syndrome]], [[acute myeloid leukemia]], [[bladder cancer]], [[lung cancer]], [[gastrointestinal tract cancer]], [[breast cancer]], [[skin cancer]], [[Head and neck cancer|squamous cell carcinoma of the head and neck]])<br />
****Cardiovascular complications (e.g., [[cardiomyopathies]], [[congestive heart failure]], [[myocardial infarction]])<br />
****[[Infertility]]<br />
****[[Hypothyroidism]]<br />
****[[Growth hormone deficiency]]<br />
****[[Insulin resistance]]<br />
****[[Hypogonadism]]<br />
****[[Dyslipidemia]]<br />
****[[Post-traumatic stress disorder]]<br />
****[[Progressive multifocal leukoencephalopathy]] (in patients treated with an [[Rituximab|anti-CD20 monoclonal antibody]])<br />
<br />
===Prognosis===<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_natural_history,_complications_and_prognosis&diff=1722600B-cell lymphoma natural history, complications and prognosis2022-04-19T18:53:44Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
==Natural History, Complications, and Prognosis==<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]].<br />
===Natural History===<br />
*30% of patients with [[Hodgkin's lymphoma]] may progress to develop [[B symptoms]] (unintentional weight loss, fever, drenching night sweats)<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref>. <br />
*Natural history of [[Non-Hodgkin lymphomas]] significantly varies depending on the subtype and it's prognosis. If left untreated, aggresive lymphomas present with B symptoms, and patients' condition significantly deteriorates within days or weeks. On the other hand, indolent lymphomas usually present with waxing and waning [[lymphadenopathy]] for years<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref>.<br />
===Complications===<br />
*Complications of B cell lymphomas are usually due to side effects of [[chemotherapy]] and/or [[radiotherapy]]. <br />
**Complications in patients with [[Hodgkin's lymphoma]] include:<br />
***Common complications of chemotherapy and/or radiotherapy in patients with [[Hodgkin's lymphoma]] include:<ref name="Cancer.ca">Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015</ref><ref name="urlRadiation Therapy for Hodgkin Lymphoma | Radiation for Hodgkin Disease">{{cite web |url=https://www.cancer.org/cancer/hodgkin-lymphoma/treating/radiation.html |title=Radiation Therapy for Hodgkin Lymphoma &#124; Radiation for Hodgkin Disease |format= |work= |accessdate=}}</ref><br />
****Nausea and vomiting<br />
****[[Xerostomia]]<br />
****Sore throat<br />
****[[Dysgeusia]]<br />
****Diarrhea<br />
****Fatigue<br />
****Skin reactions<br />
***Late and long-term complications of chemotherapy and/or [[radiotherapy]] in patients with Hodgkin's lymphoma include:<ref name="Cancer.ca">Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015</ref><ref name="urlRadiation Therapy for Hodgkin Lymphoma | Radiation for Hodgkin Disease">{{cite web |url=https://www.cancer.org/cancer/hodgkin-lymphoma/treating/radiation.html |title=Radiation Therapy for Hodgkin Lymphoma &#124; Radiation for Hodgkin Disease |format= |work= |accessdate=}}</ref><br />
****Second malignancies (e.g., [[breast cancer]], [[lung cancer]], [[colon cancer]], [[leukemias]], [[non-Hodgkin lymphomas]], etc.)<ref name="pmid26699166">{{cite journal |vauthors=Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE |title=Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma |journal=N Engl J Med |volume=373 |issue=26 |pages=2499–511 |date=December 2015 |pmid=26699166 |doi=10.1056/NEJMoa1505949 |url=}}</ref><ref name="pmid16369761">{{cite journal |vauthors=Borchmann P, Behringer K, Josting A, Rueffer JU, Schnell R, Diehl V, Engert A, Kvasnicka HM, Thiele J |title=[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma] |language=German |journal=Pathologe |volume=27 |issue=1 |pages=47–52 |date=February 2006 |pmid=16369761 |doi=10.1007/s00292-005-0811-0 |url=}}</ref><ref name="pmid10653864">{{cite journal |vauthors=van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R, Aleman BM |title=Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood |journal=J Clin Oncol |volume=18 |issue=3 |pages=487–97 |date=February 2000 |pmid=10653864 |doi=10.1200/JCO.2000.18.3.487 |url=}}</ref><br />
****[[Infertility]]<br />
****Infections<br />
****[[Hypothyroidism]]<br />
****[[Dyspnea]]<br />
****Growth delay in children<br />
****[[Cardiovascular]] complications (e.g., [[congestive heart failure]], [[cardiomyopathies]], [[myocardial infarction]], [[pericarditis]], [[arryhtmias]], etc.)<ref name="pmid21483015">{{cite journal |vauthors=Ng AK, LaCasce A, Travis LB |title=Long-term complications of lymphoma and its treatment |journal=J Clin Oncol |volume=29 |issue=14 |pages=1885–92 |date=May 2011 |pmid=21483015 |doi=10.1200/JCO.2010.32.8427 |url=}}</ref><ref name="pmid20858859">{{cite journal |vauthors=Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, Marcus KJ, Stevenson MA, Chen MH, Ng AK |title=Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation |journal=Blood |volume=117 |issue=2 |pages=412–8 |date=January 2011 |pmid=20858859 |doi=10.1182/blood-2010-06-291328 |url=}}</ref><ref name="pmid24559287">{{cite journal |vauthors=Zinzani PL, Federico M, Oliva S, Pinto A, Rigacci L, Specchia G, Tucci A, Vitolo U |title=The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma |journal=Leuk Lymphoma |volume=56 |issue=1 |pages=12–25 |date=January 2015 |pmid=24559287 |doi=10.3109/10428194.2014.894187 |url=}}</ref><br />
**Complications in patients with [[non-Hodgkin's lymphoma]] include:<br />
***Common complications of [[chemotherapy]] and/or [[radiotherapy]] in patients with [[non-Hodgkin lymphoma]] include:<br />
****Nausea and vomiting<br />
****Fatigue<br />
****[[Myelosuppression]]<br />
****[[Febrile neutropenia]]<br />
****[[Immunosuppression]]<br />
***Late and long-term complications of chemotherapy and/or radiotherapy in patients with non-Hodgkin lymphoma include:<br />
****Second malignancies (e.g., myelodysplastic syndrome, AML, bladder cancer, lung cancer, malignancies of gastrointestinal tract, breast cancer, skin cancer, squamous cell carcinoma of the head and neck)<br />
****Cardiovascular complications (e.g., [[cardiomyopathies]], [[congestive heart failure]], [[myocardial infarction]])<br />
****[[Infertility]]<br />
****[[Hypothyroidism]]<br />
****[[Growth hormone deficiency]]<br />
****[[Insulin resistance]]<br />
****[[Hypogonadism]]<br />
****[[Dyslipidemia]]<br />
****[[Post-traumatic stress disorder]]<br />
****[[Progressive multifocal leukoencephalopathy]] (in patients treated with an anti-CD20 monoclonal antibody)<br />
<br />
===Prognosis===<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_natural_history,_complications_and_prognosis&diff=1722599B-cell lymphoma natural history, complications and prognosis2022-04-19T18:50:18Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
==Natural History, Complications, and Prognosis==<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]].<br />
===Natural History===<br />
*30% of patients with [[Hodgkin's lymphoma]] may progress to develop [[B symptoms]] (unintentional weight loss, fever, drenching night sweats)<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref>. <br />
*Natural history of [[Non-Hodgkin lymphomas]] significantly varies depending on the subtype and it's prognosis. If left untreated, aggresive lymphomas present with B symptoms, and patients' condition significantly deteriorates within days or weeks. On the other hand, indolent lymphomas usually present with waxing and waning [[lymphadenopathy]] for years<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref>.<br />
===Complications===<br />
*Complications of B cell lymphomas are usually due to side effects of [[chemotherapy]] and/or [[radiotherapy]]. <br />
**Common complications of chemotherapy and/or radiotherapy in patients with Hodgkin's lymphoma include:<ref name="Cancer.ca">Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015</ref><ref name="urlRadiation Therapy for Hodgkin Lymphoma | Radiation for Hodgkin Disease">{{cite web |url=https://www.cancer.org/cancer/hodgkin-lymphoma/treating/radiation.html |title=Radiation Therapy for Hodgkin Lymphoma &#124; Radiation for Hodgkin Disease |format= |work= |accessdate=}}</ref><br />
***Nausea and vomiting<br />
***[[Xerostomia]]<br />
***Sore throat<br />
***[[Dysgeusia]]<br />
***Diarrhea<br />
***Fatigue<br />
***Skin reactions<br />
**Late and long-term complications of chemotherapy and/or [[radiotherapy]] in patients with Hodgkin's lymphoma include:<ref name="Cancer.ca">Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015</ref><ref name="urlRadiation Therapy for Hodgkin Lymphoma | Radiation for Hodgkin Disease">{{cite web |url=https://www.cancer.org/cancer/hodgkin-lymphoma/treating/radiation.html |title=Radiation Therapy for Hodgkin Lymphoma &#124; Radiation for Hodgkin Disease |format= |work= |accessdate=}}</ref><br />
***Second malignancies (e.g., [[breast cancer]], [[lung cancer]], [[colon cancer]], [[leukemias]], [[non-Hodgkin lymphomas]], etc.)<ref name="pmid26699166">{{cite journal |vauthors=Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE |title=Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma |journal=N Engl J Med |volume=373 |issue=26 |pages=2499–511 |date=December 2015 |pmid=26699166 |doi=10.1056/NEJMoa1505949 |url=}}</ref><ref name="pmid16369761">{{cite journal |vauthors=Borchmann P, Behringer K, Josting A, Rueffer JU, Schnell R, Diehl V, Engert A, Kvasnicka HM, Thiele J |title=[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma] |language=German |journal=Pathologe |volume=27 |issue=1 |pages=47–52 |date=February 2006 |pmid=16369761 |doi=10.1007/s00292-005-0811-0 |url=}}</ref><ref name="pmid10653864">{{cite journal |vauthors=van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R, Aleman BM |title=Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood |journal=J Clin Oncol |volume=18 |issue=3 |pages=487–97 |date=February 2000 |pmid=10653864 |doi=10.1200/JCO.2000.18.3.487 |url=}}</ref><br />
***[[Infertility]]<br />
***Infections<br />
***[[Hypothyroidism]]<br />
***[[Dyspnea]]<br />
***Growth delay in children<br />
***[[Cardiovascular]] complications (e.g., [[congestive heart failure]], [[cardiomyopathies]], [[myocardial infarction]], [[pericarditis]], [[arryhtmias]], etc.)<ref name="pmid21483015">{{cite journal |vauthors=Ng AK, LaCasce A, Travis LB |title=Long-term complications of lymphoma and its treatment |journal=J Clin Oncol |volume=29 |issue=14 |pages=1885–92 |date=May 2011 |pmid=21483015 |doi=10.1200/JCO.2010.32.8427 |url=}}</ref><ref name="pmid20858859">{{cite journal |vauthors=Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, Marcus KJ, Stevenson MA, Chen MH, Ng AK |title=Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation |journal=Blood |volume=117 |issue=2 |pages=412–8 |date=January 2011 |pmid=20858859 |doi=10.1182/blood-2010-06-291328 |url=}}</ref><ref name="pmid24559287">{{cite journal |vauthors=Zinzani PL, Federico M, Oliva S, Pinto A, Rigacci L, Specchia G, Tucci A, Vitolo U |title=The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma |journal=Leuk Lymphoma |volume=56 |issue=1 |pages=12–25 |date=January 2015 |pmid=24559287 |doi=10.3109/10428194.2014.894187 |url=}}</ref><br />
**Common complications of [[chemotherapy]] and/or [[radiotherapy]] in patients with [[non-Hodgkin lymphoma]] include:<br />
**Nausea and vomiting<br />
**Fatigue<br />
**[[Myelosuppression]]<br />
**[[Febrile neutropenia]]<br />
**[[Immunosuppression]]<br />
**Late and long-term complications of chemotherapy and/or radiotherapy in patients with non-Hodgkin lymphoma include:<br />
***Second malignancies (e.g., myelodysplastic syndrome, AML, bladder cancer, lung cancer, malignancies of gastrointestinal tract, breast cancer, skin cancer, squamous cell carcinoma of the head and neck)<br />
***Cardiovascular complications (e.g., [[cardiomyopathies]], [[congestive heart failure]], [[myocardial infarction]])<br />
***[[Infertility]]<br />
***[[Hypothyroidism]]<br />
***[[Growth hormone deficiency]]<br />
***[[Insulin resistance]]<br />
***[[Hypogonadism]]<br />
***[[Dyslipidemia]]<br />
***[[Post-traumatic stress disorder]]<br />
***[[Progressive multifocal leukoencephalopathy]] (in patients treated with an anti-CD20 monoclonal antibody)<br />
<br />
===Prognosis===<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_natural_history,_complications_and_prognosis&diff=1722574B-cell lymphoma natural history, complications and prognosis2022-04-17T09:40:43Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
==Natural History, Complications, and Prognosis==<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]].<br />
===Natural History===<br />
*30% of patients with [[Hodgkin's lymphoma]] may progress to develop [[B symptoms]] (unintentional weight loss, fever, drenching night sweats)<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref>. <br />
*Natural history of [[Non-Hodgkin lymphomas]] significantly varies depending on the subtype and it's prognosis. If left untreated, aggresive lymphomas present with B symptoms, and patients' condition significantly deteriorates within days or weeks. On the other hand, indolent lymphomas usually present with waxing and waning [[lymphadenopathy]] for years<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref>.<br />
===Complications===<br />
*Complications of B cell lymphomas are usually due to side effects of [[chemotherapy]] and/or [[radiotherapy]]. <br />
**Common complications of chemotherapy and/or radiotherapy in patients with Hodgkin's lymphoma include:<ref name="Cancer.ca">Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015</ref><ref name="urlRadiation Therapy for Hodgkin Lymphoma | Radiation for Hodgkin Disease">{{cite web |url=https://www.cancer.org/cancer/hodgkin-lymphoma/treating/radiation.html |title=Radiation Therapy for Hodgkin Lymphoma &#124; Radiation for Hodgkin Disease |format= |work= |accessdate=}}</ref><br />
***Nausea and vomiting<br />
***[[Xerostomia]]<br />
***Sore throat<br />
***[[Dysgeusia]]<br />
***Diarrhea<br />
***Fatigue<br />
***Skin reactions<br />
**Late and long-term complications of chemotherapy and/or [[radiotherapy]] in patients with Hodgkin's lymphoma include:<ref name="Cancer.ca">Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015</ref><ref name="urlRadiation Therapy for Hodgkin Lymphoma | Radiation for Hodgkin Disease">{{cite web |url=https://www.cancer.org/cancer/hodgkin-lymphoma/treating/radiation.html |title=Radiation Therapy for Hodgkin Lymphoma &#124; Radiation for Hodgkin Disease |format= |work= |accessdate=}}</ref><br />
***Second malignancies (e.g., [[breast cancer]], [[lung cancer]], [[colon cancer]], [[leukemias]], [[non-Hodgkin lymphomas]], etc.)<ref name="pmid26699166">{{cite journal |vauthors=Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE |title=Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma |journal=N Engl J Med |volume=373 |issue=26 |pages=2499–511 |date=December 2015 |pmid=26699166 |doi=10.1056/NEJMoa1505949 |url=}}</ref><ref name="pmid16369761">{{cite journal |vauthors=Borchmann P, Behringer K, Josting A, Rueffer JU, Schnell R, Diehl V, Engert A, Kvasnicka HM, Thiele J |title=[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma] |language=German |journal=Pathologe |volume=27 |issue=1 |pages=47–52 |date=February 2006 |pmid=16369761 |doi=10.1007/s00292-005-0811-0 |url=}}</ref><ref name="pmid10653864">{{cite journal |vauthors=van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R, Aleman BM |title=Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood |journal=J Clin Oncol |volume=18 |issue=3 |pages=487–97 |date=February 2000 |pmid=10653864 |doi=10.1200/JCO.2000.18.3.487 |url=}}</ref><br />
***[[Infertility]]<br />
***Infections<br />
***[[Hypothyroidism]]<br />
***[[Dyspnea]]<br />
***Growth delay in children<br />
***Cardiovascular complications (e.g., [[congestive heart failure]], [[cardiomyopathies]], [[myocardial infarction]], [[pericarditis]], [[arryhtmias]], etc.)<ref name="pmid21483015">{{cite journal |vauthors=Ng AK, LaCasce A, Travis LB |title=Long-term complications of lymphoma and its treatment |journal=J Clin Oncol |volume=29 |issue=14 |pages=1885–92 |date=May 2011 |pmid=21483015 |doi=10.1200/JCO.2010.32.8427 |url=}}</ref><ref name="pmid20858859">{{cite journal |vauthors=Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, Marcus KJ, Stevenson MA, Chen MH, Ng AK |title=Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation |journal=Blood |volume=117 |issue=2 |pages=412–8 |date=January 2011 |pmid=20858859 |doi=10.1182/blood-2010-06-291328 |url=}}</ref><ref name="pmid24559287">{{cite journal |vauthors=Zinzani PL, Federico M, Oliva S, Pinto A, Rigacci L, Specchia G, Tucci A, Vitolo U |title=The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma |journal=Leuk Lymphoma |volume=56 |issue=1 |pages=12–25 |date=January 2015 |pmid=24559287 |doi=10.3109/10428194.2014.894187 |url=}}</ref><br />
**Common complications of chemotherapy and/or radiotherapy in patients with non-Hodgkin lymphoma include:<br />
===Prognosis===<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_natural_history,_complications_and_prognosis&diff=1722573B-cell lymphoma natural history, complications and prognosis2022-04-17T09:39:59Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
==Natural History, Complications, and Prognosis==<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]].<br />
===Natural History===<br />
*30% of patients with [[Hodgkin's lymphoma]] may progress to develop [[B symptoms]] (unintentional weight loss, fever, drenching night sweats)<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref>. <br />
*Natural history of [[Non-Hodgkin lymphomas]] significantly varies depending on the subtype and it's prognosis. If left untreated, aggresive lymphomas present with B symptoms, and patients' condition significantly deteriorates within days or weeks. On the other hand, indolent lymphomas usually present with waxing and waning [[lymphadenopathy]] for years<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref>.<br />
===Complications===<br />
*Complications of B cell lymphomas are usually due to side effects of [[chemotherapy]] and/or [[radiotherapy]]. <br />
**Common complications of chemotherapy and/or radiotherapy in patients with Hodgkin's lymphoma include:<ref name="Cancer.ca">Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015</ref><br />
***Nausea and vomiting<br />
***[[Xerostomia]]<br />
***Sore throat<br />
***[[Dysgeusia]]<br />
***Diarrhea<br />
***Fatigue<br />
***Skin reactions<br />
**Late and long-term complications of chemotherapy and/or [[radiotherapy]] in patients with Hodgkin's lymphoma include:<ref name="Cancer.ca">Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015</ref><br />
***Second malignancies (e.g., [[breast cancer]], [[lung cancer]], [[colon cancer]], [[leukemias]], [[non-Hodgkin lymphomas]], etc.)<ref name="pmid26699166">{{cite journal |vauthors=Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE |title=Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma |journal=N Engl J Med |volume=373 |issue=26 |pages=2499–511 |date=December 2015 |pmid=26699166 |doi=10.1056/NEJMoa1505949 |url=}}</ref><ref name="pmid16369761">{{cite journal |vauthors=Borchmann P, Behringer K, Josting A, Rueffer JU, Schnell R, Diehl V, Engert A, Kvasnicka HM, Thiele J |title=[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma] |language=German |journal=Pathologe |volume=27 |issue=1 |pages=47–52 |date=February 2006 |pmid=16369761 |doi=10.1007/s00292-005-0811-0 |url=}}</ref><ref name="pmid10653864">{{cite journal |vauthors=van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R, Aleman BM |title=Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood |journal=J Clin Oncol |volume=18 |issue=3 |pages=487–97 |date=February 2000 |pmid=10653864 |doi=10.1200/JCO.2000.18.3.487 |url=}}</ref><br />
***[[Infertility]]<br />
***Infections<br />
***[[Hypothyroidism]]<br />
***[[Dyspnea]]<br />
***Growth delay in children<br />
***Cardiovascular complications (e.g., [[congestive heart failure]], [[cardiomyopathies]], [[myocardial infarction]], [[pericarditis]], [[arryhtmias]], etc.)<ref name="pmid21483015">{{cite journal |vauthors=Ng AK, LaCasce A, Travis LB |title=Long-term complications of lymphoma and its treatment |journal=J Clin Oncol |volume=29 |issue=14 |pages=1885–92 |date=May 2011 |pmid=21483015 |doi=10.1200/JCO.2010.32.8427 |url=}}</ref><ref name="pmid20858859">{{cite journal |vauthors=Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, Marcus KJ, Stevenson MA, Chen MH, Ng AK |title=Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation |journal=Blood |volume=117 |issue=2 |pages=412–8 |date=January 2011 |pmid=20858859 |doi=10.1182/blood-2010-06-291328 |url=}}</ref><ref name="pmid24559287">{{cite journal |vauthors=Zinzani PL, Federico M, Oliva S, Pinto A, Rigacci L, Specchia G, Tucci A, Vitolo U |title=The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma |journal=Leuk Lymphoma |volume=56 |issue=1 |pages=12–25 |date=January 2015 |pmid=24559287 |doi=10.3109/10428194.2014.894187 |url=}}</ref><br />
**Common complications of chemotherapy and/or radiotherapy in patients with non-Hodgkin lymphoma include:<br />
===Prognosis===<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_natural_history,_complications_and_prognosis&diff=1722570B-cell lymphoma natural history, complications and prognosis2022-04-17T09:19:46Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
==Natural History, Complications, and Prognosis==<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]].<br />
===Natural History===<br />
*30% of patients with [[Hodgkin's lymphoma]] may progress to develop [[B symptoms]] (unintentional weight loss, fever, drenching night sweats)<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref>. <br />
*Natural history of [[Non-Hodgkin lymphomas]] significantly varies depending on the subtype and it's prognosis. If left untreated, aggresive lymphomas present with B symptoms, and patients' condition significantly deteriorates within days or weeks. On the other hand, indolent lymphomas usually present with waxing and waning [[lymphadenopathy]] for years<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref>.<br />
===Complications===<br />
*Complications of B cell lymphomas are usually due to side effects of [[chemotherapy]] and/or [[radiotherapy]]. <br />
**Common complications of chemotherapy in patients with Hodgkin's lymphoma include:<ref name="Cancer.ca">Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015</ref><br />
***Nausea and vomiting<br />
***Sore throat<br />
***[[Dysgeusia]]<br />
***Diarrhea<br />
***Fatigue<br />
***Skin reactions<br />
**Late and long-term complications of chemotherapy in patients with Hodgkin's lymphoma include:<ref name="Cancer.ca">Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015</ref><br />
***Second malignancies (e.g., [[breast cancer]], [[lung cancer]], [[colon cancer]], [[leukemias]], [[non-Hodgkin lymphomas]], etc.)<ref name="pmid26699166">{{cite journal |vauthors=Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE |title=Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma |journal=N Engl J Med |volume=373 |issue=26 |pages=2499–511 |date=December 2015 |pmid=26699166 |doi=10.1056/NEJMoa1505949 |url=}}</ref><ref name="pmid16369761">{{cite journal |vauthors=Borchmann P, Behringer K, Josting A, Rueffer JU, Schnell R, Diehl V, Engert A, Kvasnicka HM, Thiele J |title=[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma] |language=German |journal=Pathologe |volume=27 |issue=1 |pages=47–52 |date=February 2006 |pmid=16369761 |doi=10.1007/s00292-005-0811-0 |url=}}</ref><ref name="pmid10653864">{{cite journal |vauthors=van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R, Aleman BM |title=Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood |journal=J Clin Oncol |volume=18 |issue=3 |pages=487–97 |date=February 2000 |pmid=10653864 |doi=10.1200/JCO.2000.18.3.487 |url=}}</ref><br />
***[[Infertility]]<br />
***Infections<br />
***[[Hypothyroidism]]<br />
***[[Dyspnea]]<br />
***Cardiovascular complications (e.g., [[congestive heart failure]], [[cardiomyopathies]], [[myocardial infarction]], [[pericarditis]], [[arryhtmias]], etc.)<ref name="pmid21483015">{{cite journal |vauthors=Ng AK, LaCasce A, Travis LB |title=Long-term complications of lymphoma and its treatment |journal=J Clin Oncol |volume=29 |issue=14 |pages=1885–92 |date=May 2011 |pmid=21483015 |doi=10.1200/JCO.2010.32.8427 |url=}}</ref><ref name="pmid20858859">{{cite journal |vauthors=Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, Marcus KJ, Stevenson MA, Chen MH, Ng AK |title=Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation |journal=Blood |volume=117 |issue=2 |pages=412–8 |date=January 2011 |pmid=20858859 |doi=10.1182/blood-2010-06-291328 |url=}}</ref><ref name="pmid24559287">{{cite journal |vauthors=Zinzani PL, Federico M, Oliva S, Pinto A, Rigacci L, Specchia G, Tucci A, Vitolo U |title=The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma |journal=Leuk Lymphoma |volume=56 |issue=1 |pages=12–25 |date=January 2015 |pmid=24559287 |doi=10.3109/10428194.2014.894187 |url=}}</ref><br />
===Prognosis===<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_natural_history,_complications_and_prognosis&diff=1722397B-cell lymphoma natural history, complications and prognosis2022-04-11T02:54:47Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
==Natural History, Complications, and Prognosis==<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]].<br />
===Natural History===<br />
*30% of patients with [[Hodgkin's lymphoma]] may progress to develop B symptoms (unintentional weight loss, fever, drenching night sweats)<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref>. <br />
*Natural history of [[Non-Hodgkin lymphomas]] significantly varies depending on the subtype and it's prognosis. If left untreated, aggresive lymphomas present with B symptoms, and patients' condition significantly deteriorates within days or weeks. On the other hand, indolent lymphomas usually present with waxing and waning lymphadenopathy for years<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref>.<br />
===Complications===<br />
<br />
===Prognosis===<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_screening&diff=1722396B-cell lymphoma screening2022-04-11T02:24:08Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
There is insufficient evidence to recommend routine screening for B-cell lymphomas.<br />
==Screening==<br />
There is insufficient evidence to recommend routine screening for B-cell lymphomas. <br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_screening&diff=1722395B-cell lymphoma screening2022-04-11T02:23:52Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
There is insufficient evidence to recommend routine screening for B-cell lymphomas.<br />
==Screening==<br />
There is insufficient evidence to recommend routine screening for B-cell lymphomas. <br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]<br />
y]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_screening&diff=1722394B-cell lymphoma screening2022-04-11T02:23:41Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
There is insufficient evidence to recommend routine screening for B-cell lymphomas.<br />
==Screening==<br />
There is insufficient evidence to recommend routine screening for B-cell lymphomas. <br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]<br />
y]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_risk_factors&diff=1720031B-cell lymphoma risk factors2022-02-22T19:27:59Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
Common risk factors in the development of B-cell lymphoma include family history, [[infections]], [[obesity]], drugs, environmental factors, [[genetic mutations]], [[immunodeficiency]] states, and [[autoimmune diseases]].<br />
==Risk Factors==<br />
===Common Risk Factors===<br />
*Common risk factors in the development of [disease name] include:<ref name="pmid15803153">{{cite journal |vauthors=Küppers R |title=Mechanisms of B-cell lymphoma pathogenesis |journal=Nat Rev Cancer |volume=5 |issue=4 |pages=251–62 |date=April 2005 |pmid=15803153 |doi=10.1038/nrc1589 |url=}}</ref><ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid32809661">{{cite journal |vauthors=Jamil A, Mukkamalla SKR |title= |journal= |volume= |issue= |pages= |date= |pmid=32809661 |doi= |url=}}</ref><ref name="pmid26744436">{{cite journal |vauthors=Flowers CR, Skibola CF |title=Identifying risk factors for B-cell lymphoma |journal=Blood |volume=127 |issue=1 |pages=10–1 |date=January 2016 |pmid=26744436 |pmc=4705601 |doi=10.1182/blood-2015-11-677203 |url=}}</ref><br />
**First degree family history of [[non-Hodgkin lymphoma]]<br />
**Infections such as [[Epstein Barr virus]] (EBV), [[HTLV-1]], [[Kaposi's sarcoma-associated herpesvirus|HHV8]], [[Hepatitis C|Hepatitis C virus]], [[Helicobacter pylori]], and [[Coxiella burnetii]]<br />
**[[Obesity]] (BMI≥30 kg/m2) in young patients<br />
**Drugs such as [[phenytoin]], [[digoxin]], and TNF-a antagonist<br />
**Environmental factors such as pesticides, solvents, organic chemicals, radiation exposure, etc.<br />
**[[B-cell lymphoma pathophysiology|Genetic mutations]]<br />
**Immunodeficiency states such as [[severe combined immunodeficiency]], [[Wiskott-Aldrich syndrome]], [[HIV AIDS|AIDS]], and [[immunosuppressive therapy]]<br />
**Autoimmune diseases such as [[rheumatoid arthritis]], [[Sjögren's syndrome]], [[celiac disease]], and [[Hashimoto's thyroiditis]]<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_risk_factors&diff=1720030B-cell lymphoma risk factors2022-02-22T19:27:30Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
Common risk factors in the development of B-cell lymphoma include family history, infections, obesity, drugs, environmental factors, genetic mutations, [[immunodeficiency]] states, and [[autoimmune diseases]].<br />
==Risk Factors==<br />
===Common Risk Factors===<br />
*Common risk factors in the development of [disease name] include:<ref name="pmid15803153">{{cite journal |vauthors=Küppers R |title=Mechanisms of B-cell lymphoma pathogenesis |journal=Nat Rev Cancer |volume=5 |issue=4 |pages=251–62 |date=April 2005 |pmid=15803153 |doi=10.1038/nrc1589 |url=}}</ref><ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid32809661">{{cite journal |vauthors=Jamil A, Mukkamalla SKR |title= |journal= |volume= |issue= |pages= |date= |pmid=32809661 |doi= |url=}}</ref><ref name="pmid26744436">{{cite journal |vauthors=Flowers CR, Skibola CF |title=Identifying risk factors for B-cell lymphoma |journal=Blood |volume=127 |issue=1 |pages=10–1 |date=January 2016 |pmid=26744436 |pmc=4705601 |doi=10.1182/blood-2015-11-677203 |url=}}</ref><br />
**First degree family history of [[non-Hodgkin lymphoma]]<br />
**Infections such as [[Epstein Barr virus]] (EBV), [[HTLV-1]], [[Kaposi's sarcoma-associated herpesvirus|HHV8]], [[Hepatitis C|Hepatitis C virus]], [[Helicobacter pylori]], and [[Coxiella burnetii]]<br />
**[[Obesity]] (BMI≥30 kg/m2) in young patients<br />
**Drugs such as [[phenytoin]], [[digoxin]], and TNF-a antagonist<br />
**Environmental factors such as pesticides, solvents, organic chemicals, radiation exposure, etc.<br />
**[[B-cell lymphoma pathophysiology|Genetic mutations]]<br />
**Immunodeficiency states such as [[severe combined immunodeficiency]], [[Wiskott-Aldrich syndrome]], [[HIV AIDS|AIDS]], and [[immunosuppressive therapy]]<br />
**Autoimmune diseases such as [[rheumatoid arthritis]], [[Sjögren's syndrome]], [[celiac disease]], and [[Hashimoto's thyroiditis]]<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_risk_factors&diff=1720028B-cell lymphoma risk factors2022-02-22T19:27:06Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
Common risk factors in the development of B-cell lymphoma include family history, infections, obesity, drugs, environmental factors, genetic mutations, [[immunodeficiency]] states, and [[autoimmune diseases]].<br />
==Risk Factors==<br />
===Common Risk Factors===<br />
*Common risk factors in the development of [disease name] include:<ref name="pmid15803153">{{cite journal |vauthors=Küppers R |title=Mechanisms of B-cell lymphoma pathogenesis |journal=Nat Rev Cancer |volume=5 |issue=4 |pages=251–62 |date=April 2005 |pmid=15803153 |doi=10.1038/nrc1589 |url=}}</ref><ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid32809661">{{cite journal |vauthors=Jamil A, Mukkamalla SKR |title= |journal= |volume= |issue= |pages= |date= |pmid=32809661 |doi= |url=}}</ref><ref name="pmid26744436">{{cite journal |vauthors=Flowers CR, Skibola CF |title=Identifying risk factors for B-cell lymphoma |journal=Blood |volume=127 |issue=1 |pages=10–1 |date=January 2016 |pmid=26744436 |pmc=4705601 |doi=10.1182/blood-2015-11-677203 |url=}}</ref><br />
**First degree family history of [[non-Hodgkin lymphoma]]<br />
**Infections such as [[Epstein Barr virus]] (EBV), [[HTLV-1]], [[Kaposi's sarcoma-associated herpesvirus|HHV8]], [[Hepatitis C|Hepatitis C virus]], [[Helicobacter pylori]], [[Coxiella burnetii]]<br />
**[[Obesity]] (BMI≥30 kg/m2) in young patients<br />
**Drugs such as [[phenytoin]], [[digoxin]], TNF-a antagonist<br />
**Environmental factors such as pesticides, solvents, organic chemicals, radiation exposure, etc.<br />
**[[B-cell lymphoma pathophysiology|Genetic mutations]]<br />
**Immunodeficiency states such as [[severe combined immunodeficiency]], [[Wiskott-Aldrich syndrome]], [[HIV AIDS|AIDS]], and [[immunosuppressive therapy]]<br />
**Autoimmune diseases such as [[rheumatoid arthritis]], [[Sjögren's syndrome]], [[celiac disease]], and [[Hashimoto's thyroiditis]]<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_risk_factors&diff=1720027B-cell lymphoma risk factors2022-02-22T19:26:51Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
Common risk factors in the development of B-cell lymphoma include family history, infections, obesity, drugs, environmental factors, genetic mutations, [[immunodeficiency]] states, [[autoimmune diseases]].<br />
==Risk Factors==<br />
===Common Risk Factors===<br />
*Common risk factors in the development of [disease name] include:<ref name="pmid15803153">{{cite journal |vauthors=Küppers R |title=Mechanisms of B-cell lymphoma pathogenesis |journal=Nat Rev Cancer |volume=5 |issue=4 |pages=251–62 |date=April 2005 |pmid=15803153 |doi=10.1038/nrc1589 |url=}}</ref><ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid32809661">{{cite journal |vauthors=Jamil A, Mukkamalla SKR |title= |journal= |volume= |issue= |pages= |date= |pmid=32809661 |doi= |url=}}</ref><ref name="pmid26744436">{{cite journal |vauthors=Flowers CR, Skibola CF |title=Identifying risk factors for B-cell lymphoma |journal=Blood |volume=127 |issue=1 |pages=10–1 |date=January 2016 |pmid=26744436 |pmc=4705601 |doi=10.1182/blood-2015-11-677203 |url=}}</ref><br />
**First degree family history of [[non-Hodgkin lymphoma]]<br />
**Infections such as [[Epstein Barr virus]] (EBV), [[HTLV-1]], [[Kaposi's sarcoma-associated herpesvirus|HHV8]], [[Hepatitis C|Hepatitis C virus]], [[Helicobacter pylori]], [[Coxiella burnetii]]<br />
**[[Obesity]] (BMI≥30 kg/m2) in young patients<br />
**Drugs such as [[phenytoin]], [[digoxin]], TNF-a antagonist<br />
**Environmental factors such as pesticides, solvents, organic chemicals, radiation exposure, etc.<br />
**[[B-cell lymphoma pathophysiology|Genetic mutations]]<br />
**Immunodeficiency states such as [[severe combined immunodeficiency]], [[Wiskott-Aldrich syndrome]], [[HIV AIDS|AIDS]], and [[immunosuppressive therapy]]<br />
**Autoimmune diseases such as [[rheumatoid arthritis]], [[Sjögren's syndrome]], [[celiac disease]], and [[Hashimoto's thyroiditis]]<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_risk_factors&diff=1720026B-cell lymphoma risk factors2022-02-22T19:25:11Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
Common risk factors in the development of B-cell lymphoma include infections, drugs, environmental factors, [[immunodeficiency]] states, and [[autoimmune diseases]].<br />
==Risk Factors==<br />
===Common Risk Factors===<br />
*Common risk factors in the development of [disease name] include:<ref name="pmid15803153">{{cite journal |vauthors=Küppers R |title=Mechanisms of B-cell lymphoma pathogenesis |journal=Nat Rev Cancer |volume=5 |issue=4 |pages=251–62 |date=April 2005 |pmid=15803153 |doi=10.1038/nrc1589 |url=}}</ref><ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid32809661">{{cite journal |vauthors=Jamil A, Mukkamalla SKR |title= |journal= |volume= |issue= |pages= |date= |pmid=32809661 |doi= |url=}}</ref><ref name="pmid26744436">{{cite journal |vauthors=Flowers CR, Skibola CF |title=Identifying risk factors for B-cell lymphoma |journal=Blood |volume=127 |issue=1 |pages=10–1 |date=January 2016 |pmid=26744436 |pmc=4705601 |doi=10.1182/blood-2015-11-677203 |url=}}</ref><br />
**First degree family history of [[non-Hodgkin lymphoma]]<br />
**Infections such as [[Epstein Barr virus]] (EBV), [[HTLV-1]], [[Kaposi's sarcoma-associated herpesvirus|HHV8]], [[Hepatitis C|Hepatitis C virus]], [[Helicobacter pylori]], [[Coxiella burnetii]]<br />
**[[Obesity]] (BMI≥30 kg/m2) in young patients<br />
**Drugs such as [[phenytoin]], [[digoxin]], TNF-a antagonist<br />
**Environmental factors such as pesticides, solvents, organic chemicals, radiation exposure, etc.<br />
**[[B-cell lymphoma pathogenesis|Genetic mutations]]<br />
**Immunodeficiency states such as [[severe combined immunodeficiency]], [[Wiskott-Aldrich syndrome]], [[HIV AIDS|AIDS]], and [[immunosuppressive therapy]]<br />
**Autoimmune diseases such as [[rheumatoid arthritis]], [[Sjögren's syndrome]], [[celiac disease]], and [[Hashimoto's thyroiditis]]<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_risk_factors&diff=1720025B-cell lymphoma risk factors2022-02-22T18:57:57Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
Common risk factors in the development of B-cell lymphoma include infections, drugs, environmental factors, [[immunodeficiency]] states, and [[autoimmune diseases]].<br />
==Risk Factors==<br />
===Common Risk Factors===<br />
*Common risk factors in the development of [disease name] include:<ref name="pmid15803153">{{cite journal |vauthors=Küppers R |title=Mechanisms of B-cell lymphoma pathogenesis |journal=Nat Rev Cancer |volume=5 |issue=4 |pages=251–62 |date=April 2005 |pmid=15803153 |doi=10.1038/nrc1589 |url=}}</ref><ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid32809661">{{cite journal |vauthors=Jamil A, Mukkamalla SKR |title= |journal= |volume= |issue= |pages= |date= |pmid=32809661 |doi= |url=}}</ref><br />
**Infections such as [[Epstein Barr virus]] (EBV), [[HTLV-1]], [[Kaposi's sarcoma-associated herpesvirus|HHV8]], [[Hepatitis C|Hepatitis C virus]], [[Helicobacter pylori]]<br />
**Drugs such as [[phenytoin]], [[digoxin]], TNF-a antagonist<br />
**Environmental factors such as pesticides, solvents, organic chemicals, radiation exposure, etc<br />
**Immunodeficiency states such as [[severe combined immunodeficiency]], [[Wiskott-Aldrich syndrome]], [[HIV AIDS|AIDS]], and [[immunosuppressive therapy]]<br />
**Autoimmune diseases such as [[rheumatoid arthritis]], [[Sjögren's syndrome]], [[celiac disease]], and [[Hashimoto's thyroiditis]]<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_causes&diff=1720024B-cell lymphoma causes2022-02-22T18:57:34Z<p>Adnan Ezici: </p>
<hr />
<div>{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
The exact cause of B-cell lymphoma has not been identified. However, there are several factors associated with B-cell lymphoma including [[infections]], drugs, environmental factors, [[immunodeficiency]] states, and [[autoimmune diseases]].<br />
==Causes==<br />
The exact cause of B-cell lymphoma has not been identified. However, there are several factors associated with the development of B-cell lymphoma including:<ref name="pmid15803153">{{cite journal |vauthors=Küppers R |title=Mechanisms of B-cell lymphoma pathogenesis |journal=Nat Rev Cancer |volume=5 |issue=4 |pages=251–62 |date=April 2005 |pmid=15803153 |doi=10.1038/nrc1589 |url=}}</ref><ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid32809661">{{cite journal |vauthors=Jamil A, Mukkamalla SKR |title= |journal= |volume= |issue= |pages= |date= |pmid=32809661 |doi= |url=}}</ref><br />
*Infections such as [[Epstein Barr virus]] (EBV), [[HTLV-1]], [[Kaposi's sarcoma-associated herpesvirus|HHV8]], [[Hepatitis C|Hepatitis C virus]], [[Helicobacter pylori]]<br />
*Drugs such as [[phenytoin]], [[digoxin]], TNF-a antagonist<br />
*Environmental factors such as pesticides, solvents, organic chemicals, radiation exposure, etc.<br />
*Immunodeficiency states such as [[severe combined immunodeficiency]], [[Wiskott-Aldrich syndrome]], [[HIV AIDS|AIDS]], and [[immunosuppressive therapy]]<br />
*Autoimmune diseases such as [[rheumatoid arthritis]], [[Sjögren's syndrome]], [[celiac disease]], and [[Hashimoto's thyroiditis]]<br />
==References==<br />
{{Reflist|2}}<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_epidemiology_and_demographics&diff=1719883B-cell lymphoma epidemiology and demographics2022-02-20T09:59:30Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most of the [[Non-Hodgkin lymphomas]]. The incidence of [[non-Hodgkin lymphoma]] is approximately 18.6 per 100,000 individuals worldwide. The incidence of [[Hodgkin's lymphoma]] is approximately 2-3 per 100,000 individuals in populations of European ancestry. In the year 2018, the mortality rate of [[non-Hodgkin lymphoma]] is approximately 5.1/100,000. In the year 2017, the mortality rate of [[Hodgkin's lymphoma]] is approximately 0.41/100,000.<br />
==Epidemiology and Demographics==<br />
<br />
===Incidence===<br />
The incidence of [[non-Hodgkin lymphoma]] is approximately 18.6 per 100,000 individuals worldwide.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref> The incidence of [[Hodgkin's lymphoma]] is approximately 2-3 per 100,000 individuals in populations of European ancestry.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref><br />
===Case-fatality rate/Mortality rate===<br />
In the year 2018, the mortality rate of [[non-Hodgkin lymphoma]] is approximately 5.1/100,000.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref> In the year 2017, the mortality rate of [[Hodgkin's lymphoma]] is approximately 0.41/100,000.<ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref><br />
===Age===<br />
[[Non-Hodgkin lymphoma]] (NHL) commonly affects individuals older than 65 years of age. However, some subtypes of NHL (i.e., [[Burkitt lymphoma]]) show a bimodal age distribution. [[Hodgkin's lymphoma]] has a bimodal age distribution with the highest incidence in patients (20-39) years of age and older than 60 years of age.<ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref><br />
===Race===<br />
In the US, [[Non-Hodgkin lymphoma]] (NHL) usually affects individuals of the white and non-Hispanic races. Asian/Pacific Islander, American Indian and black individuals are less likely to develop NHL.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref>. [[Hodgkin's lymphoma]] shows age-specific racial disparities. In patients aged <65 years, individuals of the white race have the highest incidence of Hodgkin's lymphoma. On the other hand, in patients over 65 years old, individuals of Hispanics have the highest incidence of Hodgkin's lymphoma. Regardless of the age, Asian/Pacific Islanders (A/PI) are less likely to develop Hodgkin's lymphoma.<ref name="pmid22241896">{{cite journal |vauthors=Evens AM, Antillón M, Aschebrook-Kilfoy B, Chiu BC |title=Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis |journal=Ann Oncol |volume=23 |issue=8 |pages=2128–2137 |date=August 2012 |pmid=22241896 |doi=10.1093/annonc/mdr578 |url=}}</ref><br />
===Gender===<br />
Men are more commonly affected by [[Non-Hodgkin lymphoma]] (NHL) than women. The male to female ratio is approximately 2 to 1, however, it's known that the male to female ratio is up to 4 in certain subtypes of NHL<ref name="pmid25386354">{{cite journal |vauthors=Horesh N, Horowitz NA |title=Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy |journal=Rambam Maimonides Med J |volume=5 |issue=4 |pages=e0038 |date=October 2014 |pmid=25386354 |pmc=4222427 |doi=10.5041/RMMJ.10172 |url=}}</ref><ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref>. Men are more commonly affected by [[Hodgkin's lymphoma]] than women. The male to female ratio is approximately 3 to 2.3, however, it's known that the male to female ratio varies depending on the age. In children aged 15 to 19 year, females are more commonly affected with Hodgkin's lymphoma than males with the M/F ratio of approximately 0.8. <ref name=NCI>{{cite web | title = National Caner Institute Childhood Hodgkin Lymphoma Treatment| url =http://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq#cit/section_1.3}}</ref><ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref><br />
===Region===<br />
The majority of endemic [[Burkitt Lymphoma]], a subtype of NHL, cases are reported in subequatorial Africa.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref>. Countries with the highest incidence (age-standardized) of [[Hodgkin's lymphoma]] include Lebanon, Greece, and Montenegro.<ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref><br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_epidemiology_and_demographics&diff=1719882B-cell lymphoma epidemiology and demographics2022-02-20T09:35:17Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
<br />
==Epidemiology and Demographics==<br />
<br />
===Incidence===<br />
The incidence of [[non-Hodgkin lymphoma]] is approximately 18.6 per 100,000 individuals worldwide.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref> The incidence of [[Hodgkin's lymphoma]] is approximately 2-3 per 100,000 individuals in populations of European ancestry.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref><br />
===Case-fatality rate/Mortality rate===<br />
In year 2018, the mortality rate of [[non-Hodgkin lymphoma]] is approximately 5.1/100,000.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref> In year 2017, the mortality rate of [[Hodgkin's lymphoma]] is approximately 0.41/100,000.<ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref><br />
===Age===<br />
[[Non-Hodgkin lymphoma]] (NHL) commonly affects individuals older than 65 years of age. However, some subtypes of NHL (i.e., [[Burkitt lymphoma]]) show a bimodal age distribution. [[Hodgkin's lymphoma]] has a bimodal age distribution with the highest incidence in patients (20-39) years of age and older than 60 years of age.<ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref><br />
===Race===<br />
In the US, [[Non-Hodgkin lymphoma]] (NHL) usually affects individuals of the white and non-Hispanic races. Asian/Pacific Islander, American Indian and black individuals are less likely to develop NHL.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref>. [[Hodgkin's lymphoma]] shows age-specific racial disparities. In patients aged <65 years, individuals of the white race have the highest incidence of Hodgkin's lymphoma. On the other hand, in patients over 65 years old, individuals of Hispanics have the highest incidence of Hodgkin's lymphoma. Regardless of the age, Asian/Pacific Islanders (A/PI) are less likely to develop Hodgkin's lymphoma.<ref name="pmid22241896">{{cite journal |vauthors=Evens AM, Antillón M, Aschebrook-Kilfoy B, Chiu BC |title=Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis |journal=Ann Oncol |volume=23 |issue=8 |pages=2128–2137 |date=August 2012 |pmid=22241896 |doi=10.1093/annonc/mdr578 |url=}}</ref><br />
===Gender===<br />
Men are more commonly affected by NHL than women. The male to female ratio is approximately 2 to 1, however, it's known that the male to female ratio is up to 4 in certain subtypes of NHL<ref name="pmid25386354">{{cite journal |vauthors=Horesh N, Horowitz NA |title=Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy |journal=Rambam Maimonides Med J |volume=5 |issue=4 |pages=e0038 |date=October 2014 |pmid=25386354 |pmc=4222427 |doi=10.5041/RMMJ.10172 |url=}}</ref><ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref>. Men are more commonly affected by [[Hodgkin's lymphoma]] than women. The male to female ratio is approximately 3 to 2.3, however, it's known that the male to female ratio varies depending on the age. In children aged 15 to 19 year, females are more commonly affected with Hodgkin's lymphoma than males with the M/F ratio of approximately 0.8. <ref name=NCI>{{cite web | title = National Caner Institute Childhood Hodgkin Lymphoma Treatment| url =http://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq#cit/section_1.3}}</ref><ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref><br />
===Region===<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_epidemiology_and_demographics&diff=1719881B-cell lymphoma epidemiology and demographics2022-02-20T09:04:38Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
<br />
==Epidemiology and Demographics==<br />
<br />
===Incidence===<br />
The incidence of [[non-Hodgkin lymphoma]] is approximately 18.6 per 100,000 individuals worldwide.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref> The incidence of [[Hodgkin's lymphoma]] is approximately 2-3 per 100,000 individuals in populations of European ancestry.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref><br />
===Prevalence===<br />
<br />
===Case-fatality rate/Mortality rate===<br />
In year 2018, the mortality rate of [[non-Hodgkin lymphoma]] is approximately 5.1/100,000.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref> In year 2017, the mortality rate of [[Hodgkin's lymphoma]] is approximately 0.41/100,000.<ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref><br />
===Age===<br />
[[Non-Hodgkin lymphoma]] (NHL) commonly affects individuals older than 65 years of age. However, some subtypes of NHL (i.e., [[Burkitt lymphoma]]) show a bimodal age distribution. [[Hodgkin's lymphoma]] has a bimodal age distribution with the highest incidence in patients (20-39) years of age and older than 60 years of age.<ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref><br />
===Race===<br />
In the US, [[Non-Hodgkin lymphoma]] (NHL) usually affects individuals of the white and non-Hispanic races. Asian/Pacific Islander, American Indian and black individuals are less likely to develop NHL.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref>. Hodgkin's lymphoma shows age-specific racial disparities. In patients aged <65 years, individuals of the white race have the highest incidence of Hodgkin's lymphoma. On the other hand, in patients over 65 years old, individuals of Hispanics have the highest incidence of Hodgkin's lymphoma. Regardless of the age, Asian/Pacific Islanders (A/PI) are less likely to develop Hodgkin's lymphoma.<ref name="pmid22241896">{{cite journal |vauthors=Evens AM, Antillón M, Aschebrook-Kilfoy B, Chiu BC |title=Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis |journal=Ann Oncol |volume=23 |issue=8 |pages=2128–2137 |date=August 2012 |pmid=22241896 |doi=10.1093/annonc/mdr578 |url=}}</ref><br />
===Gender===<br />
Men are more commonly affected by NHL than women. The male to female ratio is approximately 2 to 1, however, it's known that the male to female ratio is up to 4 in certain subtypes of NHL<ref name="pmid25386354">{{cite journal |vauthors=Horesh N, Horowitz NA |title=Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy |journal=Rambam Maimonides Med J |volume=5 |issue=4 |pages=e0038 |date=October 2014 |pmid=25386354 |pmc=4222427 |doi=10.5041/RMMJ.10172 |url=}}</ref><ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref>. <br />
===Region===<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_epidemiology_and_demographics&diff=1719880B-cell lymphoma epidemiology and demographics2022-02-20T08:53:06Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
<br />
==Epidemiology and Demographics==<br />
<br />
===Incidence===<br />
The incidence of [[non-Hodgkin lymphoma]] is approximately 18.6 per 100,000 individuals worldwide.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref> The incidence of [[Hodgkin's lymphoma]] is approximately 2-3 per 100,000 individuals in populations of European ancestry.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref><br />
===Prevalence===<br />
<br />
===Case-fatality rate/Mortality rate===<br />
In year 2018, the mortality rate of [[non-Hodgkin lymphoma]] is approximately 5.1/100,000.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref> In year 2017, the mortality rate of [[Hodgkin's lymphoma]] is approximately 0.41/100,000.<ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref><br />
===Age===<br />
[[Non-Hodgkin lymphoma]] (NHL) commonly affects individuals older than 65 years of age. However, some subtypes of NHL (i.e., [[Burkitt lymphoma]]) show a bimodal age distribution. [[Hodgkin's lymphoma]] has a bimodal age distribution with the highest incidence in patients (20-39) years of age and older than 60 years of age.<ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref><br />
===Race===<br />
In the US, [[Non-Hodgkin lymphoma]] (NHL) usually affects individuals of the white and non-Hispanic races. Asian/Pacific Islander, American Indian and black individuals are less likely to develop NHL.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref>. Hodgkin's lymphoma shows age-specific racial disparities. In patients aged <65 years, individuals of the white race have the highest incidence of Hodgkin's lymphoma. On the other hand, in patients over 65 years old, individuals of Hispanics have the highest incidence of Hodgkin's lymphoma. Regardless of the age, Asian/Pacific Islanders (A/PI) are less likely to develop Hodgkin's lymphoma.<ref name="pmid22241896">{{cite journal |vauthors=Evens AM, Antillón M, Aschebrook-Kilfoy B, Chiu BC |title=Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis |journal=Ann Oncol |volume=23 |issue=8 |pages=2128–2137 |date=August 2012 |pmid=22241896 |doi=10.1093/annonc/mdr578 |url=}}</ref><br />
===Gender===<br />
<br />
===Region===<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_epidemiology_and_demographics&diff=1719732B-cell lymphoma epidemiology and demographics2022-02-17T03:18:38Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
<br />
==Epidemiology and Demographics==<br />
<br />
===Incidence===<br />
The incidence of [[non-Hodgkin lymphoma]] is approximately 18.6 per 100,000 individuals worldwide.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref> The incidence of [[Hodgkin's lymphoma]] is approximately 2-3 per 100,000 individuals in populations of European ancestry.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref><br />
===Prevalence===<br />
<br />
===Case-fatality rate/Mortality rate===<br />
In year 2018, the mortality rate of [[non-Hodgkin lymphoma]] is approximately 5.1/100,000.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref> In year 2017, the mortality rate of [[Hodgkin's lymphoma]] is approximately 0.41/100,000.<ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref><br />
===Age===<br />
[[Non-Hodgkin lymphoma]] (NHL) commonly affects individuals older than 65 years of age. However, some subtypes of NHL (i.e., [[Burkitt lymphoma]]) show a bimodal age distribution. [[Hodgkin's lymphoma]] has a bimodal age distribution with the highest incidence in patients (20-39) years of age and older than 60 years of age.<ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref><br />
===Race===<br />
<br />
===Gender===<br />
<br />
===Region===<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_epidemiology_and_demographics&diff=1719731B-cell lymphoma epidemiology and demographics2022-02-17T02:55:39Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
<br />
==Epidemiology and Demographics==<br />
<br />
===Incidence===<br />
The incidence of [[non-Hodgkin lymphoma]] is approximately 18.6 per 100,000 individuals worldwide.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref> The incidence of [[Hodgkin's lymphoma]] is approximately 2-3 per 100,000 individuals in populations of European ancestry.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref><br />
===Prevalence===<br />
<br />
===Case-fatality rate/Mortality rate===<br />
In year 2018, the mortality rate of [[non-Hodgkin lymphoma]] is approximately 5.1/100,000.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref> In year 2017, the mortality rate of [[Hodgkin's lymphoma]] is approximately 0.41/100,000.<ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref><br />
===Age===<br />
<br />
===Race===<br />
<br />
===Gender===<br />
<br />
===Region===<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_epidemiology_and_demographics&diff=1719730B-cell lymphoma epidemiology and demographics2022-02-17T02:39:18Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
<br />
==Epidemiology and Demographics==<br />
<br />
===Incidence===<br />
The incidence of [[non-Hodgkin lymphoma]] is approximately 18.6 per 100,000 individuals worldwide.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref> The incidence of [[Hodgkin's lymphoma]] is approximately 2-3 per 100,000 individuals in populations of European ancestry.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref><br />
===Prevalence===<br />
<br />
===Case-fatality rate/Mortality rate===<br />
<br />
===Age===<br />
<br />
===Race===<br />
<br />
===Gender===<br />
<br />
===Region===<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_differential_diagnosis&diff=1719390B-cell lymphoma differential diagnosis2022-02-08T20:53:08Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
<br />
==Differentiating B-cell Lymphoma From Other Diseases==<br />
B-cell Lymphoma must be differentiated from other diseases that cause lymphadenopathy, fever, night sweat, or unintentional weight loss such as:<ref name="pmid27929264">{{cite journal |vauthors=Gaddey HL, Riegel AM |title=Unexplained Lymphadenopathy: Evaluation and Differential Diagnosis |journal=Am Fam Physician |volume=94 |issue=11 |pages=896–903 |date=December 2016 |pmid=27929264 |doi= |url=}}</ref><ref name="pmid32644344">{{cite journal |vauthors=Maini R, Nagalli S |title= |journal= |volume= |issue= |pages= |date= |pmid=32644344 |doi= |url=}}</ref><ref name="pmid24753638">{{cite journal |vauthors=Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A |title=Peripheral lymphadenopathy: approach and diagnostic tools |journal=Iran J Med Sci |volume=39 |issue=2 Suppl |pages=158–70 |date=March 2014 |pmid=24753638 |pmc=3993046 |doi= |url=}}</ref><ref name="pmid30020622">{{cite journal |vauthors=Freeman AM, Matto P |title= |journal= |volume= |issue= |pages= |date= |pmid=30020622 |doi= |url=}}</ref><ref name="pmid9803196">{{cite journal |vauthors=Ferrer R |title=Lymphadenopathy: differential diagnosis and evaluation |journal=Am Fam Physician |volume=58 |issue=6 |pages=1313–20 |date=October 1998 |pmid=9803196 |doi= |url=}}</ref><ref name="pmid19290029">{{cite journal |vauthors=Roca B |title=Castleman's Disease. A Review |journal=AIDS Rev |volume=11 |issue=1 |pages=3–7 |date=2009 |pmid=19290029 |doi= |url=}}</ref><br />
*[[Neoplasm]]<br />
:*[[T-cell lymphoma]]<br />
:*[[Kaposi sarcoma]]<br />
:*[[Leukemias]]<br />
:*[[breast cancer|Metastatic breast cancer]]<br />
:*[[renal cancer|Metastatic renal cancer]]<br />
:*[[thyroid cancer|Metastatic thyroid cancer]]<br />
:*[[Lung cancer|Metastatic carcinoma of the lung]]<br />
:*[[Gastric cancer|Metastatic carcinoma of the gastrointestinal system]]<br />
:*[[Neuroblastoma]]<br />
:*Retroperitoneal cancer<br />
:*[[Pediatric acute myelocytic leukemia]]<br />
:*[[Rhabdomyosarcoma]]<br />
:*[[Melanoma]]<br />
:*[[Head and neck cancer]]<br />
:*[[Castleman's disease|Castleman disease]]<br />
:*<br />
* [[Infections]]<br />
:*Bacterial<br />
:**[[Brucellosis]]<br />
:**[[Cat scratch disease]]<br />
:**[[Syphilis]]<br />
:**[[Staphylococcus]]<br />
:**[[Streptococcus]]<br />
:**[[Salmonella]]<br />
:**[[Yersinia]]<br />
:**[[Tuberculosis]]<br />
:**[[Mycobacterium avium intracellulare]]<br />
:**[[Chancroid]]<br />
:**[[Tularemia]]<br />
:**[[Typhoid fever]]<br />
:**[[Lymphogranuloma venereum]]<br />
:*Viral<br />
:**[[Infectious mononucleosis]]<br />
:**[[CMV]]<br />
:**[[HIV]]<br />
:**[[Rubella]]<br />
:**[[Roseola]]<br />
:**[[Hepatitis]]<br />
:**[[Herpes zoster]]<br />
:**[[Adenovirus]]<br />
:*[[Fungal]]<br />
:**[[Histoplasmosis]]<br />
:**[[Coccidioidomycosis]]<br />
:**[[Candida]]<br />
:*[[Parasitic]]<br />
:**[[Toxoplasmosis]]<br />
:**[[Chagas disease]]<br />
:*Other<br />
:**[[Lyme disease]]<br />
:**[[Rocky Mountain spotted fever|Rocky Mountain spotted fever (RMSF)]]<br />
* [[Autoimmune diseases]]<br />
:*[[Systemic lupus erythematosus causes|Systemic lupus erythematosus]]<br />
:*[[Sjögren's syndrome]]<br />
:*[[Amyloidosis]]<br />
:*[[Sarcoidosis]] <br />
:*[[Juvenile idiopathic arthritis|Juvenile rheumatoid arthritis (JRA)]]<br />
:*[[Eosinophilic granulomatosis with polyangiitis]]<br />
:*[[Adult-onset Still's disease]]<br />
:*[[Dermatomyositis]]<br />
*Miscellaneous conditions<br />
:*[[Sarcoidosis]]<br />
:*[[Kawasaki disease]]<br />
:*[[Kikuchi disease]]<br />
:*[[Kimura disease]]<br />
*[[Iatrogenic]]<br />
:*[[Medications]]<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_differential_diagnosis&diff=1719389B-cell lymphoma differential diagnosis2022-02-08T20:47:38Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
<br />
==Differentiating B-cell Lymphoma From Other Diseases==<br />
B-cell Lymphoma must be differentiated from other diseases that cause lymphadenopathy, fever, night sweat, or unintentional weight loss such as:<ref name="pmid27929264">{{cite journal |vauthors=Gaddey HL, Riegel AM |title=Unexplained Lymphadenopathy: Evaluation and Differential Diagnosis |journal=Am Fam Physician |volume=94 |issue=11 |pages=896–903 |date=December 2016 |pmid=27929264 |doi= |url=}}</ref><ref name="pmid32644344">{{cite journal |vauthors=Maini R, Nagalli S |title= |journal= |volume= |issue= |pages= |date= |pmid=32644344 |doi= |url=}}</ref><ref name="pmid24753638">{{cite journal |vauthors=Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A |title=Peripheral lymphadenopathy: approach and diagnostic tools |journal=Iran J Med Sci |volume=39 |issue=2 Suppl |pages=158–70 |date=March 2014 |pmid=24753638 |pmc=3993046 |doi= |url=}}</ref><ref name="pmid30020622">{{cite journal |vauthors=Freeman AM, Matto P |title= |journal= |volume= |issue= |pages= |date= |pmid=30020622 |doi= |url=}}</ref><ref name="pmid9803196">{{cite journal |vauthors=Ferrer R |title=Lymphadenopathy: differential diagnosis and evaluation |journal=Am Fam Physician |volume=58 |issue=6 |pages=1313–20 |date=October 1998 |pmid=9803196 |doi= |url=}}</ref><ref name="pmid19290029">{{cite journal |vauthors=Roca B |title=Castleman's Disease. A Review |journal=AIDS Rev |volume=11 |issue=1 |pages=3–7 |date=2009 |pmid=19290029 |doi= |url=}}</ref><br />
*[[Neoplasm]]<br />
:*[[T-cell lymphoma]]<br />
:*[[Kaposi sarcoma]]<br />
:*[[Leukemias]]<br />
:*[[breast cancer|Metastatic breast cancer]]<br />
:*[[renal cancer|Metastatic renal cancer]]<br />
:*[[thyroid cancer|Metastatic thyroid cancer]]<br />
:*[[Lung cancer|Metastatic carcinoma of the lung]]<br />
:*[[Gastric cancer|Metastatic carcinoma of the gastrointestinal system]]<br />
:*[[Neuroblastoma]]<br />
:*Retroperitoneal cancer<br />
:*[[Pediatric acute myelocytic leukemia]]<br />
:*[[Rhabdomyosarcoma]]<br />
:*[[Melanoma]]<br />
:*[[Head and neck cancer]]<br />
:*[[Castleman's disease|Castleman disease]]<br />
:*<br />
* [[Infections]]<br />
:*Bacterial<br />
:**[[Brucellosis]]<br />
:**[[Cat scratch disease]]<br />
:**[[Syphilis]]<br />
:**[[Staphylococcus]]<br />
:**[[Streptococcus]]<br />
:**[[Salmonella]]<br />
:**[[Yersinia]]<br />
:**[[Tuberculosis]]<br />
:**[[Chancroid]]<br />
:**[[Tularemia]]<br />
:**[[Typhoid fever]]<br />
:**[[Lymphogranuloma venereum]]<br />
:*Viral<br />
:**[[Infectious mononucleosis]]<br />
:**[[CMV]]<br />
:**[[HIV]]<br />
:**[[Rubella]]<br />
:**[[Roseola]]<br />
:**[[Hepatitis]]<br />
:**[[Herpes zoster]]<br />
:**[[Adenovirus]]<br />
:*Granulamatous<br />
:**[[Histoplasmosis]]<br />
:**[[Cryptococcosis]]<br />
:**[[Silicosis]]<br />
:**[[Coccidioidomycosis]]<br />
:**[[Berylliosis]]<br />
:*Other<br />
:**[[Fungal]]<br />
:**[[Toxoplasmosis]]<br />
:**[[Lyme disease]]<br />
:**[[Rocky Mountain spotted fever|Rocky Mountain spotted fever (RMSF)]]<br />
* [[Autoimmune diseases]]<br />
:*[[Systemic lupus erythematosus causes|Systemic lupus erythematosus]]<br />
:*[[Sjögren's syndrome]]<br />
:*[[Amyloidosis]]<br />
:*[[Sarcoidosis]] <br />
:*[[Rheumatoid arthritis]]<br />
:*[[Eosinophilic granulomatosis with polyangiitis]]<br />
:*[[Adult-onset Still's disease]]<br />
:*[[Dermatomyositis]]<br />
*Miscellaneous conditions<br />
:*[[Sarcoidosis]]<br />
:*[[Kawasaki disease]]<br />
:*[[Kikuchi disease]]<br />
:*[[Kimura disease]]<br />
*[[Iatrogenic]]<br />
:*[[Medications]]<br />
:*[[Serum sickness]]<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_differential_diagnosis&diff=1719388B-cell lymphoma differential diagnosis2022-02-08T20:36:46Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
<br />
==Differentiating B-cell Lymphoma From Other Diseases==<br />
B-cell Lymphoma must be differentiated from other diseases that cause lymphadenopathy, fever, night sweat, or unintentional weight loss such as:<ref name="pmid27929264">{{cite journal |vauthors=Gaddey HL, Riegel AM |title=Unexplained Lymphadenopathy: Evaluation and Differential Diagnosis |journal=Am Fam Physician |volume=94 |issue=11 |pages=896–903 |date=December 2016 |pmid=27929264 |doi= |url=}}</ref><ref name="pmid32644344">{{cite journal |vauthors=Maini R, Nagalli S |title= |journal= |volume= |issue= |pages= |date= |pmid=32644344 |doi= |url=}}</ref><ref name="pmid24753638">{{cite journal |vauthors=Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A |title=Peripheral lymphadenopathy: approach and diagnostic tools |journal=Iran J Med Sci |volume=39 |issue=2 Suppl |pages=158–70 |date=March 2014 |pmid=24753638 |pmc=3993046 |doi= |url=}}</ref><ref name="pmid30020622">{{cite journal |vauthors=Freeman AM, Matto P |title= |journal= |volume= |issue= |pages= |date= |pmid=30020622 |doi= |url=}}</ref><ref name="pmid9803196">{{cite journal |vauthors=Ferrer R |title=Lymphadenopathy: differential diagnosis and evaluation |journal=Am Fam Physician |volume=58 |issue=6 |pages=1313–20 |date=October 1998 |pmid=9803196 |doi= |url=}}</ref><ref name="pmid19290029">{{cite journal |vauthors=Roca B |title=Castleman's Disease. A Review |journal=AIDS Rev |volume=11 |issue=1 |pages=3–7 |date=2009 |pmid=19290029 |doi= |url=}}</ref><br />
*[[Neoplasm]]<br />
:*[[T-cell lymphoma]]<br />
:*[[Kaposi sarcoma]]<br />
:*[[Leukemias]]<br />
:*[[breast cancer|Metastatic breast cancer]]<br />
:*[[renal cancer|Metastatic renal cancer]]<br />
:*[[thyroid cancer|Metastatic thyroid cancer]]<br />
:*[[Lung cancer|Metastatic carcinoma of the lung]]<br />
:*[[Gastric cancer|Metastatic carcinoma of the gastrointestinal system]]<br />
:*[[Neuroblastoma]]<br />
:*Retroperitoneal cancer<br />
:*[[Pediatric acute myelocytic leukemia]]<br />
:*[[Rhabdomyosarcoma]]<br />
:*[[Melanoma]]<br />
:*[[Head and neck cancer]]<br />
:*[[Castleman's disease|Castleman disease]]<br />
:*<br />
* [[Infections]]<br />
:*Bacterial<br />
:**[[Brucellosis]]<br />
:**[[Cat scratch disease]]<br />
:**[[Syphilis]]<br />
:**[[Tuberculosis]]<br />
:**[[Chancroid]]<br />
:**[[Tularemia]]<br />
:**[[Typhoid fever]]<br />
:**[[Lymphogranuloma venereum]]<br />
:*Viral<br />
:**[[Infectious mononucleosis]]<br />
:**[[CMV]]<br />
:**[[HIV]]<br />
:**[[Rubella]]<br />
:**[[Hepatitis]]<br />
:**[[Herpes zoster]]<br />
:**[[Adenovirus]]<br />
:*Granulamatous<br />
:**[[Histoplasmosis]]<br />
:**[[Cryptococcosis]]<br />
:**[[Silicosis]]<br />
:**[[Coccidioidomycosis]]<br />
:**[[Berylliosis]]<br />
:*Other<br />
:**[[Toxoplasmosis]]<br />
:**[[Lyme disease]]<br />
:**[[Rocky Mountain spotted fever|Rocky Mountain spotted fever (RMSF)]]<br />
* [[Autoimmune diseases]]<br />
:*[[Systemic lupus erythematosus causes|Systemic lupus erythematosus]]<br />
:*[[Sjögren's syndrome]]<br />
:*[[Sarcoidosis]] <br />
:*[[Rheumatoid arthritis]]<br />
:*[[Still disease]]<br />
:*[[Dermatomyositis]]<br />
*Miscellaneous conditions<br />
:*[[Sarcoidosis]]<br />
:*[[Kawasaki disease]]<br />
:*[[Kikuchi disease]]<br />
:*[[Kimura disease]]<br />
<br />
<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_differential_diagnosis&diff=1719387B-cell lymphoma differential diagnosis2022-02-08T20:33:34Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
<br />
==Differentiating B-cell Lymphoma From Other Diseases==<br />
B-cell Lymphoma must be differentiated from other diseases that cause lymphadenopathy, fever, night sweat, or unintentional weight loss such as:<ref name="pmid27929264">{{cite journal |vauthors=Gaddey HL, Riegel AM |title=Unexplained Lymphadenopathy: Evaluation and Differential Diagnosis |journal=Am Fam Physician |volume=94 |issue=11 |pages=896–903 |date=December 2016 |pmid=27929264 |doi= |url=}}</ref><ref name="pmid32644344">{{cite journal |vauthors=Maini R, Nagalli S |title= |journal= |volume= |issue= |pages= |date= |pmid=32644344 |doi= |url=}}</ref><ref name="pmid24753638">{{cite journal |vauthors=Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A |title=Peripheral lymphadenopathy: approach and diagnostic tools |journal=Iran J Med Sci |volume=39 |issue=2 Suppl |pages=158–70 |date=March 2014 |pmid=24753638 |pmc=3993046 |doi= |url=}}</ref><ref name="pmid30020622">{{cite journal |vauthors=Freeman AM, Matto P |title= |journal= |volume= |issue= |pages= |date= |pmid=30020622 |doi= |url=}}</ref><ref name="pmid9803196">{{cite journal |vauthors=Ferrer R |title=Lymphadenopathy: differential diagnosis and evaluation |journal=Am Fam Physician |volume=58 |issue=6 |pages=1313–20 |date=October 1998 |pmid=9803196 |doi= |url=}}</ref><ref name="pmid19290029">{{cite journal |vauthors=Roca B |title=Castleman's Disease. A Review |journal=AIDS Rev |volume=11 |issue=1 |pages=3–7 |date=2009 |pmid=19290029 |doi= |url=}}</ref><br />
*[[Neoplasm]]<br />
:*[[T-cell lymphoma]]<br />
:*[[Kaposi sarcoma]]<br />
:*[[Leukemias]]<br />
:*[[breast cancer|Metastatic breast cancer]]<br />
:*[[renal cancer|Metastatic renal cancer]]<br />
:*[[thyroid cancer|Metastatic thyroid cancer]]<br />
:*[[Lung cancer|Metastatic carcinoma of the lung]]<br />
:*[[Gastric cancer|Metastatic carcinoma of the gastrointestinal system]]<br />
:*[[Neuroblastoma]]<br />
:*Retroperitoneal cancer<br />
:*[[Pediatric acute myelocytic leukemia]]<br />
:*[[Rhabdomyosarcoma]]<br />
:*[[Melanoma]]<br />
:*[[Head and neck cancer]]<br />
:*[[Castleman's disease|Castleman disease]]<br />
:*<br />
* [[Infections]]<br />
:*Bacterial<br />
:**[[Brucellosis]]<br />
:**[[Cat scratch disease]]<br />
:**[[Syphilis]]<br />
:**[[Tuberculosis]]<br />
:**[[Chancroid]]<br />
:**[[Tularemia]]<br />
:**[[Typhoid fever]]<br />
:**[[Lymphogranuloma venereum]]<br />
:*Viral<br />
:**[[Infectious mononucleosis]]<br />
:**[[CMV]]<br />
:**[[HIV]]<br />
:**[[Rubella]]<br />
:**[[Hepatitis]]<br />
:**[[Herpes zoster]]<br />
:**[[Adenovirus]]<br />
:*Granulamatous<br />
:**[[Histoplasmosis]]<br />
:**[[Cryptococcosis]]<br />
:**[[Silicosis]]<br />
:**[[Coccidioidomycosis]]<br />
:**[[Berylliosis]]<br />
:*Other<br />
:**[[Toxoplasmosis]]<br />
:**[[Lyme disease]]<br />
:**[[Rocky Mountain spotted fever|Rocky Mountain spotted fever (RMSF)]]<br />
* [[Autoimmune diseases]]<br />
:*[[Systemic lupus erythematosus causes|Systemic lupus erythematosus]]<br />
:*[[Sjögren's syndrome]]<br />
:*[[Sarcoidosis]] <br />
:*[[Rheumatoid arthritis]]<br />
:*[[Still disease]]<br />
:*[[Dermatomyositis]]<br />
<br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_differential_diagnosis&diff=1719386B-cell lymphoma differential diagnosis2022-02-08T20:22:46Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
<br />
==Differentiating B-cell Lymphoma From Other Diseases==<br />
B-cell Lymphoma must be differentiated from other diseases that cause lymphadenopathy, fever, night sweats, weight loss, and rash such as:<ref name="pmid27929264">{{cite journal |vauthors=Gaddey HL, Riegel AM |title=Unexplained Lymphadenopathy: Evaluation and Differential Diagnosis |journal=Am Fam Physician |volume=94 |issue=11 |pages=896–903 |date=December 2016 |pmid=27929264 |doi= |url=}}</ref><ref name="pmid32644344">{{cite journal |vauthors=Maini R, Nagalli S |title= |journal= |volume= |issue= |pages= |date= |pmid=32644344 |doi= |url=}}</ref><ref name="pmid24753638">{{cite journal |vauthors=Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A |title=Peripheral lymphadenopathy: approach and diagnostic tools |journal=Iran J Med Sci |volume=39 |issue=2 Suppl |pages=158–70 |date=March 2014 |pmid=24753638 |pmc=3993046 |doi= |url=}}</ref><ref name="pmid30020622">{{cite journal |vauthors=Freeman AM, Matto P |title= |journal= |volume= |issue= |pages= |date= |pmid=30020622 |doi= |url=}}</ref><ref name="pmid9803196">{{cite journal |vauthors=Ferrer R |title=Lymphadenopathy: differential diagnosis and evaluation |journal=Am Fam Physician |volume=58 |issue=6 |pages=1313–20 |date=October 1998 |pmid=9803196 |doi= |url=}}</ref><ref name="pmid19290029">{{cite journal |vauthors=Roca B |title=Castleman's Disease. A Review |journal=AIDS Rev |volume=11 |issue=1 |pages=3–7 |date=2009 |pmid=19290029 |doi= |url=}}</ref><br />
*[[Neoplasm]]<br />
:*[[T-cell lymphoma]]<br />
:*[[Kaposi sarcoma]]<br />
:*[[Leukemias]]<br />
:*[[breast cancer|Metastatic breast cancer]]<br />
:*[[renal cancer|Metastatic renal cancer]]<br />
:*[[thyroid cancer|Metastatic thyroid cancer]]<br />
:*[[Lung cancer|Metastatic carcinoma of the lung]]<br />
:*[[Gastric cancer|Metastatic carcinoma of the gastrointestinal system]]<br />
:*[[Neuroblastoma]]<br />
:*Retroperitoneal cancer<br />
:*[[Pediatric acute myelocytic leukemia]]<br />
:*[[Rhabdomyosarcoma]]<br />
:*[[Melanoma]]<br />
:*[[Head and neck cancer]]<br />
:*[[Castleman's disease|Castleman disease]]<br />
:*<br />
* [[Infections]]<br />
:*Bacterial<br />
:**[[Brucellosis]]<br />
:**[[Cat scratch disease]]<br />
:**[[Syphilis]]<br />
:**[[Tuberculosis]]<br />
:**[[Chancroid]]<br />
:**[[Tularemia]]<br />
:**[[Typhoid fever]]<br />
:**[[Lymphogranuloma venereum]]<br />
:*Viral<br />
:**[[Infectious mononucleosis]]<br />
:**[[CMV]]<br />
:**[[HIV]]<br />
:**[[Rubella]]<br />
:**[[Hepatitis]]<br />
:**[[Herpes zoster]]<br />
:**[[Adenovirus]]<br />
:*Granulamatous<br />
:**[[Histoplasmosis]]<br />
:**[[Cryptococcosis]]<br />
:**[[Silicosis]]<br />
:**[[Coccidioidomycosis]]<br />
:**[[Berylliosis]]<br />
:*Other<br />
:**[[Toxoplasmosis]]<br />
:**[[Lyme disease]]<br />
:**[[Rocky Mountain spotted fever|Rocky Mountain spotted fever (RMSF)]]<br />
* [[Autoimmune diseases]]<br />
:*[[Systemic lupus erythematosus causes|Systemic lupus erythematosus]]<br />
:*[[Sjögren's syndrome]]<br />
:*[[Sarcoidosis]] <br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_differential_diagnosis&diff=1719385B-cell lymphoma differential diagnosis2022-02-08T20:06:45Z<p>Adnan Ezici: </p>
<hr />
<div>__NOTOC__<br />
{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
<br />
==Differentiating B-cell Lymphoma From Other Diseases==<br />
B-cell Lymphoma must be differentiated from other diseases that cause lymphadenopathy, fever, night sweats, weight loss, and rash such as:<ref name="pmid27929264">{{cite journal |vauthors=Gaddey HL, Riegel AM |title=Unexplained Lymphadenopathy: Evaluation and Differential Diagnosis |journal=Am Fam Physician |volume=94 |issue=11 |pages=896–903 |date=December 2016 |pmid=27929264 |doi= |url=}}</ref><ref name="pmid32644344">{{cite journal |vauthors=Maini R, Nagalli S |title= |journal= |volume= |issue= |pages= |date= |pmid=32644344 |doi= |url=}}</ref><ref name="pmid24753638">{{cite journal |vauthors=Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A |title=Peripheral lymphadenopathy: approach and diagnostic tools |journal=Iran J Med Sci |volume=39 |issue=2 Suppl |pages=158–70 |date=March 2014 |pmid=24753638 |pmc=3993046 |doi= |url=}}</ref><ref name="pmid30020622">{{cite journal |vauthors=Freeman AM, Matto P |title= |journal= |volume= |issue= |pages= |date= |pmid=30020622 |doi= |url=}}</ref><ref name="pmid9803196">{{cite journal |vauthors=Ferrer R |title=Lymphadenopathy: differential diagnosis and evaluation |journal=Am Fam Physician |volume=58 |issue=6 |pages=1313–20 |date=October 1998 |pmid=9803196 |doi= |url=}}</ref><br />
*[[Neoplasm]]<br />
:*[[T-cell lymphoma]]<br />
:*[[Kaposi sarcoma]]<br />
:*[[Leukemias]]<br />
:*[[breast cancer|Metastatic breast cancer]]<br />
:*[[renal cancer|Metastatic renal cancer]]<br />
:*[[thyroid cancer|Metastatic thyroid cancer]]<br />
:*[[Lung cancer|Metastatic carcinoma of the lung]]<br />
:*[[Gastric cancer|Metastatic carcinoma of the gastrointestinal system]]<br />
:*[[Neuroblastoma]]<br />
:*Retroperitoneal cancer<br />
:*[[Pediatric acute myelocytic leukemia]]<br />
:*[[Rhabdomyosarcoma]]<br />
:*[[Melanoma]]<br />
:*[[Head and neck cancer]]<br />
:*Giant lymph node hyperplasia ([[Castleman's disease|Castleman disease]])<br />
:*<br />
* [[Infections]]<br />
:*[[Syphilis]]<br />
:*[[Brucellosis]]<br />
:*[[Infectious mononucleosis]]<br />
:*[[CMV]]<br />
:*[[HIV]]<br />
:*[[Cat scratch disease]]<br />
:*[[Tuberculosis]]<br />
:*[[Toxoplasmosis]]<br />
:*<br />
* [[Autoimmune diseases]]<br />
:*[[Systemic lupus erythematosus causes|Systemic lupus erythematosus]]<br />
:*[[Sjögren's syndrome]]<br />
:*[[Sarcoidosis]] <br />
<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezicihttps://www.wikidoc.org/index.php?title=B-cell_lymphoma_causes&diff=1718970B-cell lymphoma causes2022-01-26T16:13:16Z<p>Adnan Ezici: </p>
<hr />
<div>{{B-cell lymphoma}}<br />
{{CMG}} ; {{AE}} {{Adnan Ezici}}<br />
==Overview==<br />
The exact cause of B-cell lymphoma has not been identified. However, there are several factors associated with B-cell lymphoma including [[infections]], drugs, environmental factors, [[immunodeficiency]] states, and [[autoimmune diseases]].<br />
==Causes==<br />
The exact cause of B-cell lymphoma has not been identified. However, there are several factors associated with the development of B-cell lymphoma including:<ref name="pmid15803153">{{cite journal |vauthors=Küppers R |title=Mechanisms of B-cell lymphoma pathogenesis |journal=Nat Rev Cancer |volume=5 |issue=4 |pages=251–62 |date=April 2005 |pmid=15803153 |doi=10.1038/nrc1589 |url=}}</ref><ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid32809661">{{cite journal |vauthors=Jamil A, Mukkamalla SKR |title= |journal= |volume= |issue= |pages= |date= |pmid=32809661 |doi= |url=}}</ref><br />
*Infections such as [[Epstein Barr virus]] (EBV), [[HTLV-1]], [[Kaposi's sarcoma-associated herpesvirus|HHV8]], [[Hepatitis C|Hepatitis C virus]], [[Helicobacter pylori]]<br />
*Drugs such as [[phenytoin]], [[digoxin]], TNF-a antagonist<br />
*Environmental factors such as pesticides, solvents, organic chemicals, radiation exposure, etc.<br />
*Immunodeficiency states such as [[severe combined immunodeficiency]], [[Wiskott-Aldrich syndrome]], [[HIV AIDS|AIDS]], and [[immunosuppressive therapy]]<br />
*Autoimmune diseases such as [[rheumatoid arthritis]], [[Sjögren's syndrome]], [[celiac disease]], and [[Hashimoto's thyroiditis]]<br />
==References==<br />
{{Reflist|2}}<br />
[[Category:Needs content]]<br />
<br />
[[Category:Disease]]<br />
[[Category:Types of cancer]]<br />
[[Category:Mature chapter]]<br />
[[Category:Hematology]]<br />
<br />
{{WikiDoc Help Menu}}<br />
{{WikiDoc Sources}}<br />
[[Category:Up-To-Date]]<br />
[[Category:Oncology]]<br />
[[Category:Medicine]]<br />
[[Category:Hematology]]<br />
[[Category:Immunology]]</div>Adnan Ezici